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Abstract 
Cytochrome P450 (CYP) is the predominate superfamily of enzymes 
responsible for Phase I metabolism of drugs and other xenobiotics.  Understanding 
the structural reasons for the substrate selectivity of these enzymes is important for 
both pharmacological and toxicological reasons.  Two isoforms of interest from this 
enzyme superfamily that are CYP2A13 and CYP2E1.   
 Cytochrome P450 2A13 (CYP2A13) is a lung specific enzyme known to 
activate the potent tobacco procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-
butanone (NNK) into two carcinogenic metabolites. CYP2A13 has been crystallized 
and X-ray diffraction experiments illuminated the structure of this enzyme, but with 
an unknown ligand present in the enzyme active site. This unknown ligand was 
suspected to be indole but a selective method had to be developed to differentiate 
among indole and its metabolites in the protein sample. We successfully modified a 
microbiological colorimetric assay to spectrophotometrically differentiate between 
indole and a number of possible indole metabolites in nanomolar concentrations by 
derivatization with p-dimethylaminocinnamaldehyde (DMACA). Further 
differentiation of indoles was made by mass spectrometry (HPLC–UV/vis–MS/MS) 
utilizing the chromophore generated in the DMACA conjugation as a UV signature 
for HPLC detection. The ligand in the crystallized protein was unambiguously 
identified as unsubstituted indole, which facilitated refinement of two alternate 
conformations of indole in the CYP2A13 crystal structure active site. 
vi 
Human cytochrome P450 2E1 (CYP2E1) is a xenobiotic metabolizing enzyme 
that is highly conserved among mammals.  In addition to small molecular weight 
exogenous drugs like the analgesic acetaminophen and the volatile anesthetic 
halothane, CYP2E1 is also involved in endogenous fatty acid metabolism.  To more 
fully understand the structural factors that contribute to the substrate selectivity of 
CYP2E1, it has been cocrystallized with two structurally different heme-binding 
compounds: indazole, a small molecular weight inhibitor and ω-imidazolyl-decanoic 
acid, a fatty acid analog. Comparison of the CYP2E1 structures shows that only small 
side chain movements are required for the accommodation of the much larger fatty 
acid analog.  Rotation of the side chain of F298 causes a change in the active site 
volume from 190 Å3 in the indazole-bound structure to 440 Å3 in the ω-imidazolyl-
decanoic acid-bound structure.  Future work will be focused on cocrystal structures of 
CYP2E1 with both longer and shorter chain analogs to better understand the ability of 
the enzyme to metabolize a variety of fatty acids substrates. 
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Chapter 1. 
Introduction 
Cytochrome P450:  The Superfamily 
 The metabolism of drugs and other xenobiotics typically involves two classes 
of enzymes.  These classes are referred to as Phase I and Phase II drug metabolizing 
enzymes.  The Phase I enzymes are involved in either unmasking or generating 
functional groups to increase the water solubility of a compound.  The Phase II 
enzymes are responsible for conjugating the substance to endogenous compounds 
such as sulfate, glutathione, and glucuronic acid.  The most prevalent class of 
enzymes involved in Phase I metabolism is cytochrome P450 (CYP).   
 The CYP superfamily of enzymes was originally observed by Garfinkel (1) 
and Klingenberg (2) and subsequently named for its characteristic absorbance at 450 
nm (Figure 1.1) in the presence of reducing agent (sodium dithionite) and carbon 
carbon monoxide (3-6).  This spectral feature distinguishes CYP from other heme 
containing proteins that ligate heme with histidine.  Originally, this superfamily was 
believed to be a single enzyme, but through induction and enzyme isolation it was 
shown that the entity with the characteristic absorbance peak was actually several 
related CYP isozymes (7-9).  The CYP superfamily of enzymes has monooxygenase 
activity and has been shown to catalyze many different reactions, including the 
dealkylation of hetero-atoms (N, O, and S), aliphatic and aromatic hydroxylation, and 
olefin epoxidation (10).  All of these reactions occur between the endogenous or  
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Figure 1.1:  Characteristic carbon monoxide difference spectrum.  Inset is the 
structure of the iron protoporphyrin IX bound with carbon monoxide and the thiolate 
donated by the CYP polypeptide. 
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xenobiotic substrate and an activated oxygen/iron heme thiolate complex generated in 
the CYP active site. 
The CYP Catalytic Process  
  The catalytic process of CYP is driven by reducing equivalents donated by 
NADH or NADPH.   The electrons from the reducing equivalents are shuttled to 
CYP by a redox partner.  The identity of the redox partner varies among CYPs.  
Cytosolic bacterial CYPs, as well as mitochondrial CYPs in eukaryotes, use the redox 
partners of putidaredoxin and adrenodoxin.  The microsomal CYPs in eukaryotes, 
including those responsible for drug metabolism, utilize NADPH-dependent P450 
oxidoreductase as a redox partner.  This electron transport facilitates the reductive 
cleavage of molecular oxygen that is responsible the CYP oxidative power. 
 The CYP catalytic cycle (Scheme 1.1) starts with a resting state with ferric 
heme iron complexed with water (11).  Substrate binding typically displaces the water 
molecule from the sixth coordinate position of iron.  The conversion to five 
coordinate iron changes the iron oxidative potential facilitating the first electron 
transport (12) (Scheme 1.1 3).  The newly formed ferrous iron/substrate bound form 
of the enzyme binds molecular oxygen in a coordinate covalent manner (Scheme 1.1 
4).  An additional one-electron reduction occurs generating a ferrous peroxyoxo-
anion complex (Scheme 1.1 5).  Protonation yields ferrous hydroperoxy species 
(Scheme 1.1 6), which upon loss of water generates the proposed highly reactive iron 
oxo species (Scheme 1.1 7).  The exact identity of this iron oxo species is still under 
investigation but it is proposed that this species abstracts a hydrogen atom from the 
4 
Scheme 1.1:  CYP catalytic cycle.  Steps shown in red represent uncoupled pathways. 
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substrate.  This generates a radical substrate and an iron hydroxy radical.  The two 
radicals react to generate the oxidized product and convert the protein back to its 
initial ferric state.  Several of the steps of the catalytic cycle have been confirmed 
crystallographically (11,13-15). 
 In some cases, half of the catalytic cycle can be bypassed by the addition of 
hydrogen peroxide (16) or some other peroxide source (for example cumin 
hydroperoxide (17)).  This pathway is known as the hydrogen peroxide shunt (black 
arrow in center of Scheme 1.1) and is a path directly from ferric iron to the ferrous 
hydroperoxide species.  The reverse of the hydrogen peroxide shunt is one of the two 
ways that this catalytic process can be “uncoupled” (red arrow in the center of 
Scheme 1.1).  This “uncoupling” is in reference to when reducing equivalents are 
consumed but substrate is not oxidized because of an additional route out of the 
catalytic cycle.  The other path of uncoupling is the decomposition of complex 4 of 
Scheme 1.1 to release a superoxide radical (red arrow on right in Scheme 1.1).   
These products contribute to cellular oxidative stress through lipid peroxidation, 
protein oxidation, and DNA damage. 
CYP Nomenclature:  Families and Subfamilies 
 The CYP superfamily is organized into families and subfamilies based on 
amino acid sequence identity.  The recommended nomenclature used begins with 
CYP (Cytochrome P450) followed an Arabic number and a letter (18).  The Arabic 
number and letter represent the specific family and subfamily respectively.  In most 
cases the CYP protein families are >40% percent identical, but there are exceptions to 
6 
this rule.  The subfamilies (in the mammalian system) are generally >55% identical, 
but as low as 46% when subfamilies contain proteins from distant species (18).  The 
P450 Nomenclature Committee officially designates these family and subfamily 
names.  Finally, a terminal Arabic number designates an individual isozyme. 
 The families that have the greatest impact on human xenobiotic metabolism 
are CYP1, CYP2, and CYP3.  Figure 1.2 illustrates the percent contribution of CYPs 
involved in the metabolism of clinically used drugs.  Three isozymes, namely 3A4, 
2D6, and 2C9, account for the metabolism of ~75% of the clinically used drugs (19).  
Enzymes known for the activating carcinogens include CYP1A1, CYP1A2, CYP2A6, 
CYP2E1, and CYP3A4 (20).  Since 2000, investigating the structure of these 
mammalian membrane enzymes by X-ray crystallography has become an active field 
of research, but the basic CYP fold was originally determined from soluble bacterial 
isoforms. 
CYP Structures 
  The first crystal structure from the CYP superfamily of enzymes was 
CYP101 (P450cam) from the soil bacteria Pseudomonas putida (15).  This enzyme is 
known for its metabolism of camphor hence the common name P450cam.  The general 
secondary structure features are primarily α-helical (named alphabetically) and a 
small amount of β-sheet (named β#-# with the first # indicating the sheet system and 
the second indicating which strand in the particular sheet system) (Figure 1.3).  This 
naming scheme was preserved in future structures with additional helices given the 
 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2:  CYP isoforms metabolizing clinically used drugs (19).  The size of the 
slices on the pie chart indicates the percentage contribution of the isozymes to the 
CYP catalyzed drug metabolism.  Asterisks indicate isoforms whose crystal structures 
were solved prior to this work. 
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Figure 1.3:  Overall structure of CYP101 (PDB code 2CPP (15)) colored from N-
terminus (blue) to C-terminus (red). 
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prime nomenclature.  For example, the helices F′ and G′ are helices in mammalian 
CYPs between helices F and G and that were not present in the original CYP101 
structure.    The CYP101 structure also confirmed the iron heme thiolate complex in 
the CYP active site. 
 The first mammalian CYP whose structure was solved was a mutant form of 
CYP2C5 (a rabbit CYP).  This enzyme had N-terminal transmembrane residues 3-20 
deleted to increase solubility and decrease aggregation, a 4xHis tag added to the C-
terminus to assist in purification, and internal mutations (a chimeric form with 
CYP2C3 called CYP2C5/3LVdH) (21).  This crystal structure showed a protein with 
an overall similar fold to the cytosolic bacterial forms previously crystallized.  
Compared with CYP101, the CYP2C5 structure has less β-sheet secondary structure, 
but had a new hydrophobic surface at the N-terminus of the protein thought to interact 
with the membrane.  This structure was ground breaking, showing that a mammalian 
membrane CYP can be crystallized. 
 Shortly thereafter studies performed on another rabbit P450, CYP2B4, 
showed the dramatic conformational changes allowing substrate binding.  The first 
structure (22) of CYP2B4 was in a homo-dimeric form with a histidine of one 
molecule binding to the heme iron of another and vice-versa.  This interaction yielded 
protein in an open conformation with a cleft leading directly to the active site from 
the protein surface and allowing the dimerization interactions.  When the coordinating 
histidine was mutated and an inhibitor bound in the active site, the protein crystallized 
in a closed conformation (23).  This series of studies demonstrated the extensive 
10 
flexibility of the CYP structure illustrating an induced fit type of protein/ligand 
interaction. 
 Since the crystallization of these two non-human mammalian CYPs, extensive 
effort has been placed on solving the crystal structures of human drug metabolizing 
enzymes.  Drug metabolizing CYP structures solved to date include 1A2 (24), 2A6 
(25,26), 2C8 (27), 2C9 (28), 2D6 (29) and 3A4 (30,31) (Figure 1.2 with asterisks).  
The general folds are similar but active site topology varies dramatically between 
isoforms.  This list leaves several drug-metabolizing CYPs whose structures are still 
unknown along with many other CYP proteins not involved in drug metabolism. 
CYP2E1  
The enzyme CYP2E1 was previously known as P450 “j” or ethanol-inducible 
P450.  This enzyme was first purified from human liver (32) in 1987 and the human 
gene was characterized in 1988 (33).  CYP2E1 is a microsomal CYP and is primarily 
hepatic but also can be found in extrahepatic tissues such as the lung, esophagus, and 
small intestine (34).   It has been associated with toxicity through two major 
mechanisms.  The causes of CYP2E1 associated toxicity are the generation of 
reactive metabolites, and generation of reactive oxygen species due to an uncoupled 
mechanism.    
It has been proposed that CYP2E1 is more prone to reactive oxygen species 
production than other cytochrome P450 enzymes (35).  In alcohol-induced liver 
disease (36), exposure to ethanol has been shown to induce CYP2E1 by stabilizing 
the protein and preventing its degradation.  This increase in CYP2E1 protein content 
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has been associated with the cellular stress of alcohol-induced liver disease (36).  
Recently the propensity towards uncoupling leading to health problems has become 
more controversial.  Studies utilizing in vivo levels of reactive oxygen species-
mediated isoprostanes as measures of oxidative stress have shown no detectable 
alteration in oxidative stress with induction of CYP2E1 or in CYP2E1 knockout mice 
(37). 
Two drugs CYP2E1 metabolizes to reactive metabolites are acetaminophen 
(38) and halothane (39,40).  Acetaminophen is the most widely used analgesic in the 
U.S. (41) and one of the leading causes of fatal poisonings (38).  Activation of 
acetaminophen by CYP2E1 into the strongly electrophilic N-acetyl-p-benzoquinone-
imine (NAPQI) is the initial and major step responsible for acetaminophen 
hepatotoxicity (Scheme 1.2 A).  Halothane is a volatile anesthetic whose use was 
discontinued due to severe hepatitis induced by CYP2E1 oxidation to trifluoroacetic 
acid chloride (TFAC) (Scheme 1.2 B).  TFAC covalently modifies proteins to create 
an antigen that the body recognizes in later halothane exposures, resulting in severe 
hepatic necrosis known as halothane hepatitis (39). 
In addition to acetomenophen and halothane, CYP2E1 is known to metabolize 
more than 70 low molecular weight (<100 g/mol) substrates (structures of 
representative substrates shown in Figure 1.4) including ~4% of clinically used drugs 
(19).  Most of this catalysis acts to detoxify compounds but some leads to compound 
activation.  CYP2E1 substrates include industrial solvents such as benzene, toluene, 
aniline, and halogenated solvents (42); alcohols such as ethanol (43), glycerol, 
12 
Scheme 1.2: Metabolic activation mechanism of acetaminophen (A) and halothane 
(B). (GSH = glutathione) 
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Figure 1.4:  Representative CYP2E1 substrates. 
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phenol, and p-nitrophenol (44); and bicyclic heterocycles such as caffeine (45) and 
the muscle relaxant chlorzoxazone (46).  However CYP2E1 is also known to 
metabolize endogenous fatty acids, including lipids associated with signaling 
mechanisms such as arachidonic acid (47) and epoxyeicosatrienoic acids (48).  The 
role of CYP2E1 in the metabolism of these signaling molecules may be related to its 
regulation by disease states such as obesity (49) and diabetes in rat models (50). 
Another class of compounds that CYP2E1 is known to metabolize are small 
nitrosamines.  These compounds are activated to potent DNA alkylating agents.  
Some of the nitrosamines shown to be substrates are N,N-dimethylnitrosamine (51) 
and N,N-diethylnitrosamine (51) which are primarily metabolized by CYP2E1, N-
nitrosopyrrolidine (52), N-nitroso-2,6-dimethylmorpholine (53), and to a lesser 
degree 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK) (54,55).   
 CYP2A13 
CYP2A13 is specifically expressed in the respiratory tract (56) and has been 
shown to be the most efficient activator of the tobacco smoke-derived procarcinogen 
NNK (57,58).  The gene for this enzyme was fully sequenced in 1995 (59). This 
enzyme is not known for the metabolism of drugs but has been associated with the 
activation of several pneumontoxins besides NNK including naphthalene (60), 
styrene (60), and aflatoxin B1 (61).  CYP2A13 has become an interesting drug target 
in the effort to prevent NNK metabolic activation and the subsequent lung toxicity. 
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Project Design  
 An important step in understanding the activation of NNK and in designing 
ways to inhibit its activation is to understand the structure of the enzyme responsible 
for its activation, CYP2A13.  Previous work has focused on crystallizing and solving 
the structure of CYP2A13.  The active site of CYP2A13 was occupied by an 
unknown ligand that had to be identified to complete the model of atoms in the 
experimentally determined electron density.  Several pieces of evidence suggested 
that the ligand was indole, so initially we started evaluating existing colorometric 
assays, but they were not sufficiently sensitive or selective for indole over possible 
indole metabolites.  A new method was developed that generates a chromophore and 
uses it as a handle for detection by UV/Vis detection before subsequent mass 
determination by MS/MS.   This assay was utilized to detect unsubstituted indole in 
the protein mixture used to crystallize CYP2A13 allowing indole to be subsequently 
modeled into the CYP active site. 
 As previously discussed, CYP2E1 is known for both its metabolism of small 
molecular weight substrates as well as fatty acids.  Several different approaches could 
be taken in order to understand the reasons for this substrate promiscuity.  Through 
binding and inhibition studies, a model of the enzyme active site could be generated, 
but the identity of the specific residues responsible for substrate recognition would 
still be unknown.  Through site directed mutagenesis the identity of specific residues 
involved could be identified but in some cases it is difficult to confirm that 
mutagenesis was not causing more drastic tertiary structural changes.  Our approach 
16 
to understanding how CYP2E1 can bind and metabolize these seemingly divergent 
classes of compounds is through X-ray crystallography.  This is a direct method for 
visualizing the residues involved in interacting and orienting substrates and inhibitors 
in the CYP2E1 active site.  Though no experimental structures of CYP2E1 were 
known previously, I have determined CYP2E1 structures with a molecule from each 
of the classes: indazole representing small molecular weight compounds and ω-
imidazolyl-decanoic acid representing fatty acids.  These crystal structures have 
shown that subtle movements of active site amino acid side chains allow affinity for 
these two divergent compound classes. 
Conclusion 
 The structural reasons for substrate selectivity among the isozymes discussed 
are extremely important.  Understanding the active site topology of xenobiotic 
metabolizing enzymes can aid in predicting an isoform’s metabolic profile.  This 
structural knowledge also provides a rationale for designing drugs to either inhibit 
these CYPs to prevent their toxicological actions or to generate drugs that are not 
substrates of specific cytochrome P450 enzymes.  
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Chapter 2. 
Experimental Methods and Procedures 
 The general methods described in this chapter are used in the following 
chapters.  The materials utilized were obtained from Fisher Scientific (Waltham, MA) 
unless otherwise noted. 
CPY2E1 Expression and Purification  
Protein Engineering  
The coding region for CYP2E1dH with N-terminal truncations/modifications 
and a C-terminal 4xHis tag was generated as described for CYP2B enzymes (1) using 
the plasmid pGEM 4-h2E1 as a template.  This plasmid was kindly provided by Dr. 
M. Ingelman-Sundberg (Karolinska Institute).  The resulting N-terminal and C-
terminal amino acid sequences are MAKKTSSKGKLPPGP . . . PRSHHHH (non-
native sequence underlined).  The N-terminal modification aids in protein solubility 
by deleting the N-terminal transmembrane helix and incorporating charged residues, 
while the C-terminal His tag facilitates Ni-affinity purification.  The details of 
generating the pKK2E1dH plasmid have been omitted because it was designed and 
generated by Drs. Emily E. Scott and Margit Spatzeragger before the initiation of this 
work (2).  This truncated and 4xHis tagged protein, CYP2E1dH, will be abbreviated 
CYP2E1 throughout this thesis. 
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 E. coli Transformation and Protein Expression 
 The expression process began with the transformation of the E. coli TOPP-3 
(Stratagne, La Jolla, CA) cell line with the CYP2E1-containing plasmid, pKK2E1dH.  
TOPP-3 cells (50 µL) were incubated with the CYP2E1 plasmid (1 µL) for 30 
minutes at 4 °C.  The solution was heat shocked at 42 °C for 30 to 45 seconds and 1.7 
µL of 10% (v/v in water) β-mercaptoethanol was immediately added.  The cells were 
subjected to an outgrowth step consisting of the addition of 1 mL of super optimal 
catabolite (SOC) media and incubation at 37 °C for 1 hour with shaking at 250 rpm.  
After incubation the cells were pelleted by brief centrifugation and all but 100 µL of 
supernatant removed.  The cells were resuspended in the remaining solution, spread 
on Luria-Bertani (LB) media agar plates with ampicillin at 50 µg/mL, and incubated 
at 37 °C overnight. 
 On the following day a single colony was inoculated into a 5 mL culture of 
LB media along with ampicillin (50 µg/mL) and tetracycline (25 µg/mL).  The 
antibiotic treatment provided selection for TOPP-3 cells because of their genomic 
tetracycline resistance and for specific cells containing the pKK2E1dH plasmid 
carrying the ampicillin resistance gene.  The 5 mL culture was incubated at 37 °C and 
shaken at 250 rpm for 8 hours.  Overnight starter cultures, 2 X 200 mL LB with 
ampicillin (50 µg/mL) and tetracycline (25 µg/mL), were inoculated with 50 µL of 
the 5 mL culture, incubated at 37 °C, and shaken at 250 rpm overnight.  Fifteen mL 
of this starter culture was used to inoculate each of 18 1L flasks each containing 250 
mL of terrific broth (TB) with ampicillin (50 µg/mL).  These flasks were grown to an 
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OD600 nm of 1.0-1.5 at 37 °C and shaken at 250 rpm (~2 hours).  The temperature was 
decreased to 30 °C, shaking decreased to 190 rpm, and the media supplemented with 
δ-aminolevulinic acid (20 mg/flask) as a heme precursor and isopropyl β-D-1-
thiogalactopyranoside (60 mg/flask) to induce protein expression by binding the Lac 
repressor.  Cells were grown for two days and harvested by centrifugation at 6300 x 
g.  The supernatant was discarded and pellets were stored at   -80 °C until use. 
Protein Purification and Ligand Complexation 
E. coli cells expressing CYP2E1 were resuspended in 200 mL of 20 mM 
potassium phosphate buffer pH 7.4 containing 20% glycerol and lysozyme added to 
0.3 mg/mL and stirred at 4 °C for 30 minutes.  Slowly 200 mL of water at 4 °C was 
added and the solution stirred at 4 °C for 10 minutes.  The spheroplasts were pelleted 
by centrifugation at 8800 x g for 15 minutes.  The supernatant was discarded and 
pellet resuspended in 100 mL of 100 mM potassium phosphate buffer pH 7.4 
containing 20% glycerol and 1.0 M NaCl.  The solution was homogenized with a 
tissue homogenizer and separated into three aliquots for sonication.  The solutions 
were each sonicated three times on ice for 30 seconds (Fisher Scientific, Sonic 
Dismembrator, Model 100).  Cellular debris was removed by centrifugation at 8800 x 
g for 15 minutes.  The supernatant was retained and Cymal-5 (Anatrace, Maumee, 
OH) was added to 4.8 mM and stirred at 4 °C for 60 min to solublize CYP2E1.  The 
solution was ultracentrifuged at 80,000 X g for 60 min to clarify it before the 
subsequent chromatographic steps.  The resulting supernatant was applied to NiNTA 
fastflow resin (Qiagen, Valencia, CA) and washed with 100 mM potassium phosphate 
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buffer pH 7.4 containing 20% glycerol, 300 mM NaCl, and 4.8 mM Cymal-5 to wash 
out unbound sample.  The column was then washed with 100 mM potassium 
phosphate buffer pH 7.4 containing 20% glycerol, 200 mM NaCl, 15 mM imidazole, 
and 4.8 mM Cymal-5 to remove nonspecific proteins.  CYP2E1 was eluted with 50 
mM potassium phosphate buffer pH 7.4 containing 20% glycerol, 100 mM NaCl, 180 
mM imidazole, 4.8 mM Cymal-5, and 10 mM EDTA.  CYP2E1 fractions were 
pooled and diluted 5-fold with 5 mM potassium phosphate buffer pH 7.4 containing 
20% glycerol, 5 mM EDTA, and 4.8 mM Cymal-5 to lower the ionic strength and 
facilitate binding to ion exchange resin.  This solution was applied to a 
carboxymethyl cellulose column (GE Healthcare, Uppsala, Sweden), washed with the 
dilution buffer without detergent to remove excess Cymal-5 from the protein, and 
CYP2E1 eluted with 100 mM potassium phosphate buffer pH 7.4 containing 20% 
glycerol, 500 mM NaCl, and 1 mM EDTA.  CYP2E1 fractions were concentrated to 
~1 mL using Amicon Ultra-4 centrifugal ultra filtration devices (Millipore, Billerica, 
MA, 50,000 molecular weight cut off), loaded onto a Superdex 200 16/60 gel-
filtration column (GE Healthcare, Uppsala, Sweden) and eluted with 100 mM 
potassium phosphate buffer pH 7.4 containing 20% glycerol, 500 mM NaCl, and 1 
mM EDTA.  The final CYP2E1 fractions eluted from gel-filtration were pooled, 
concentrated using Amicon Ultra-4 centrifugal ultra filtration devices (Millipore, 
Billerica, MA, 50,000 molecular weight cut off), and the buffer exchanged through 
concentrating to ~100 µL followed by diluting solution with ~4 mL of 120 mM 
potassium phosphate pH 7.4, 0.5 M sucrose, and 1 mM EDTA containing either 5 
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mM indazole or 25 mM ω-imidazolyl-decanoic acid.  This concentrating and dilution 
process was repeated 3-5 times to ensure buffer exchange.  All columns were 
monitored by UV/Vis absorbance at the wavelengths of 280 nm, 393 nm, and 424 
nm.  
 
Spectroscopic Techniques 
Absolute Spectra (3) 
To analyze protein concentration and purity during purifications as well as the 
final product, an absolute spectrum was used.  The absorbance spectrum was 
traditionally measured from 750 nm to 250 nm.  The protein spectra were background 
–subtracted with a buffer sample.  The concentration of the protein was determined 
using the Beer-Lambert law with the extinction coefficient of 0.1 mL / (nmol ∗ cm) at 
424 nm.  The relative purity was judged by comparing the Soret maximum (major 
heme absorption band occurring between 390 nm and 424 nm depending on ligand 
bound state) with the absorbance at 280 nm due tryptophan absorbance from both 
CYP2E1 and other proteins.  
CO Difference Assays (3) 
 Another way that CYP was quantified is through the spectrophotometric 
change with carbonmonoxide binding.  This method was used to quantify protein for 
the purpose of spectral binding assays.  A protein sample was prepared and a few 
grains of sodium dithionite (Sigma Aldrich, St. Louis, MO) added as a reducing agent 
(4).  The difference spectrum was acquired by the subtraction of the reduced protein 
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absorbance from the absorbance of reduced protein after exposure to 50 bubbles of 
CO (Air Liquide, Houston, TX).  The concentration of the protein was determined 
using the Beer-Lambert law with the extinction coefficient of 0.091 mL / (nmol ∗ cm) 
at 450 nm. 
Spectral Binding Assays (3) 
 Ligand binding was determined by monitoring the change in the Soret peak 
upon ligand binding.  Typically in the resting state the CYP Soret is at ~414 nm 
corresponding to six coordinate heme iron with water bound at the sixth position.  
Upon binding of a ligand, a water is displaced from the heme iron.  For a “Type I” 
ligand, the water is displaced and the ligand does not coordinate to the heme iron 
yielding five coordinate heme iron and shifting the Soret to ~390 nm.  If the ligand 
displaces the water and binds directly to the heme iron (coordinate covalently 
typically observed with a basic nitrogen) the Soret shifts to ~424 nm, which is 
indicative of a “Type II” ligand.  Experimentally, the following procedure was 
utilized to measure these spectral binding constants.  Two cuvettes were charged with 
800 µL of CYP at 1 µM diluted in 100 mM KPi pH 7.4, 20% glycerol.  One cuvette 
becomes the vessel for measuring ligand effects on absorbance while the other was 
used to correct for solvent effects.  An aliquot of ligand dissolved in vehicle is added 
to the sample cuvette along with an equal volume of vehicle to the reference cuvette 
and both are mixed.  The solutions are allowed to equilibrate for 5 minutes and the 
absorbance measured from 300 nm to 500 nm.  As this process was repeated, a peak 
and a trough form and the process was continued until there was no further change in 
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the peak to trough difference.  The peak to trough difference (ΔA) was plotted verse 
ligand concentration using Graphpad Prism 4 (Graphpad Software, San Diego, CA).  
To determine KD (the spectrally observed dissociation constant) and ΔAmax (the 
maximal peak to trough absorbance change) the data were fit using nonlinear least-
squares regression to the following equation: 
! 
"# =
"#
max
$ ligand[ ]
KD + ligand[ ]
. 
 
Crystallographic Techniques and Structure Analysis 
Hanging-drop Vapor Diffusion 
 All crystallization protocols that will be described in subsequent chapters were 
performed using the hanging drop vapor diffusion crystallization method.  This 
method utilized VDX plates (Hampton Research, HR3-142, Aliso Viejo, CA) greased 
with high vacuum grease around each well lip of the 24 well plate.  Each well was 
loaded with 750 µL of well solution.  In the center of a siliconized glass cover slip 
(Hampton Research, HR3-239, Aliso Viejo, CA) 1 µL of protein solution was placed.  
To this drop, 1 µL of well solution was directly added but not mixed.  The slip is 
inverted over the well and pressed against vacuum grease for an airtight seal.  The 
crystallization drops were allowed to equilibrate at 20 °C and were monitored for 
crystal growth.  Specific materials and methods utilized for the individual crystal 
structures including crystallization conditions, cryoprotectants, data collection, data 
processing, and phasing are discussed in the corresponding chapters. 
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VOIDOO and CAVER 
Probe-occupied voids were calculated using VOIDOO (5) with a probe radius 
of 1.4 Å and a grid mesh of 0.3 Å unless otherwise specified.  CAVER (6) 
calculations were performed utilizing a PyMOL plugin and a grid mesh of 0.8 Å. 
 
References 
1. Scott, E. E., Spatzenegger, M., and Halpert, J. R. (2001) Arch Biochem 
Biophys 395(1), 57-68 
2. Spatzenegger, M., Liu, H., Wang, Q., Debarber, A., Koop, D. R., and Halpert, 
J. R. (2003) J Pharmacol Exp Ther 304(1), 477-487 
3. Schenkman, J. B., and Jansson, I. (2006) Methods Mol Biol 320, 11-18 
4. Omura, T., and Sato, R. (1962) J Biol Chem 237, 1375-1376 
5. Kleywegt, G. J., and Jones, T. A. (1994) Acta Crystallogr. D Biol. 
Crystallogr. 50(Pt 2), 178-185 
6. Petrek, M., Otyepka, M., Banas, P., Kosinova, P., Koca, J., and Damborsky, J. 
(2006) BMC Bioinf. 7, 316 
 
 
 29 
Chapter 3. 
Identification of an Unknown Ligand Bound in the CYP2A13 
Crystal Structure:  Teaching an Old Assay New Tricks 
The experiments described in this chapter have been previously published in: 
Porubsky, P. R., Scott, E. E., and Williams, T. D. (2008) Arch Biochem Biophys 
475(1), 14-17.  Additionally, this assay was used to identify the ligand bound to 
CYP2A13, leading to the publication of its structure in: Smith, B. D., Sanders, J. L., 
Porubsky, P. R., Lushington, G. H., Stout, C. D., and Scott, E. E. (2007) J. Biol. 
Chem. 282(23), 17306-17313. 
 
Introduction 
 The lung CYP2A13 activates the potent tobacco carcinogen 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) into two possible DNA 
alkylators (1-3).  In an effort to more fully understand this enzyme’s structure and 
function, CYP2A13 has been crystallized and X-ray diffraction experiments 
performed.  These experiments illuminated the structure of this enzyme, but an 
unknown ligand was present in the enzyme active site (4).  This ligand was either co-
purified with the protein or added adventitiously.  The three following pieces of data 
suggested that the identity of the unknown ligand was indole or an indole metabolite.  
First, a 94% homologous enzyme, CYP2A6, is known to catalyze the oxidation of 
indole to several different oxidized products and pigments (5).  Some of these 
pigments were also visible during the E. coli expression of CYP2A13.  Second, 
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indole is present in the E. coli expression system due to the inherent tryptophanase 
activity of the bacteria.  Third, the electron density of the ligand in the crystal 
structure appeared to be for a planar bicyclic compound but the density covers 
enough area that ring substitutions could be possible (2|Fo|-|Fc| electron density map at 
1.0 σ shown in blue mesh in Figure 3.1).  In order to determine the identity of this 
ligand and especially to differentiate between indole and indole metabolites that could 
have been produced by CYP2A13 metabolism of indole, we developed a sensitive 
HPLC-UV/Vis-MS/MS assay (4). 
 Several different aldehyde-containing reagents have been used in microbiology 
as tools to differentiate certain genera and species of bacteria.  A positive colorimetric 
result demonstrates that the specific bacterium produces tryptophanase, an indole 
lyase.  Some of the reagents used for indole detection are p-
dimethylaminobenzaldehyde (utilized in both the Ehrlich indole reagent and the 
Kovacs indole reagent) and p-dimethylaminocinnamaldehyde (DMACA).  DMACA 
is both more rapid and long lasting, yielding results that are easier to interpret in 
bacterial assays (6).  Two advantages for our purposes were the superior sensitivity of 
the DMACA reagent and its ability to detect indole derivatives (6,7).  In fact, 
DMACA has previously been utilized for the quantitative measurement of indole-3-
methanol, also known as indole-3-carbinol, in purified plant protein samples (8).  A 
modified method of indole conjugate formation, discussed herein, has been developed 
to distinguish the identities of indole and indole-like compounds by 
spectrophotometric and HPLC-UV/Vis-MS/MS methods with increased sensitivity 
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Figure 3.1:  CYP2A13 active site with 2|Fo|-|Fc| electron density map contoured at 1.0 
σ (blue mesh).  The density is planar and with sufficient bulk for a bicyclic 
compound. 
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over previously reported techniques.  The data from a set of known compounds was 
used as standards to identify the unknown ligand in the purified protein solution used 
to generate the CYP2A13/ligand X-ray crystallographic structure (4). 
Methods 
 Materials 
 Compounds 6-hydroxyindole, 5-hydroxyindole, 4-hydroxyindole, 3-
hydroxyindole, isatin and tryptophan were obtained from Acros (Geel, Belgium), 
indole from Aldrich (St. Louis, MO), oxindole from Maybridge (Trevillett, UK) and 
p-dimethylaminocinnamaldehyde (DMACA) from Fluka (Japan).  Purified CYP2A13 
previously prepared for crystallographic purposes was obtained from Brian Smith 
(Scott Lab, Medicinal Chemistry) for analysis of unknown ligand.  All other materials 
were obtained from Fisher Scientific. 
 Spot Tests and λmax Determinations 
 In order to determine which indole compounds should be analyzed, initial spot 
tests were performed by saturating filter paper with DMACA solution (DMACA 
solution:  0.117 g of DMACA, 39 mL of ethanol, 5 mL of concentrated aqueous HCl 
and diluted to 50mL with water (6)), then spotting a solution containing indole or an 
indole derivative on the DMACA saturated filter paper with a capillary tube.  The 
compounds that turned blue like the protein/ligand derivative were analyze further.  
To quantify these observations, this derivatization was modified to a 
spectrophotometric assay.  In each coupling reaction 500 µL of indole containing 
solution (concentration between 10 ng/mL and 10 µg/mL) was combined with 250 µL 
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of DMACA solution in a cuvette.  The absorbance was then measured from 400 to 
750 nm. When purified protein samples were used, the protein (500 µL of 65 µM 
P450) was combined with DMACA reagent.  This precipitated the protein and thus 
the mixture was centrifuged at 10,600 x g for 2 minutes to clarify the solution before 
acquisition of a spectrum.  Controls were performed with indoles dissolved in the 
same buffer system as the protein to rule out complicating matrix effects on the λmax 
values of conjugates. Consistent λmax values were observed over the concentration 
ranges tested (±1 nm) and in the protein buffer matrix. 
 LC-UV/Vis-MS/MS Analysis of Derivatives 
 Identical conjugation conditions were used for LC-UV/Vis-MS/MS detection 
with indole concentrations of 0.2 pmol/µL in standards and 65 µM protein for ligand 
analysis. Separation was accomplished on 50 X 4.6 cm Alltech Altima C18 column 
with 3.0 µm particle size running at 0.3 mL/min.  HPLC was performed with the 
mobile phases (Solvent A) 99% H2O, 1% methanol, 0.06% formic acid, 10 mM 
ammonium formate and (Solvent B) 99% methanol, 1% H2O, 0.06% formic acid, 10 
mM ammonium formate.  The solvent gradient was run to 1% B by 1 min (Δ% B of 1 
%/min), then to 50% B by 2 min (Δ% B of 49 %/min), and then to 80% B by 15 min 
(Δ% B of 2.3 %/min).  The UV/Vis detector was set at 625 nm for all LC-UV/Vis-
MS/MS experiments.  A Waters 2695 chromatograph was used to develop gradients 
and present peaks to a Micromass Quattro Ultima “triple” quadrupole mass 
spectrometer with an electrospray source. 
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Results and Discussion 
The reaction between the unknown ligand from the CYP2A13 protein mixture 
and DMACA generated a conjugate that turned blue using the spot test and absorbed 
at 625 nm.  A set of indoles was initially screened by a spot test on filter paper 
saturated with DMACA solution.  The compounds yielding a blue result from the spot 
test became candidates for the unknown ligand.  Indoles were tested at concentrations 
between 10 µg/mL and 10 ng/mL (85 µM to 85 nM for indole, concentrations vary 
with molecular weight with respect to the other indoles). 
From the initial UV/Vis analysis, most of the oxidized indoles could be ruled 
out as the CYP2A13 ligand (Table 3.1). The λmax of the UV/Vis data suggested that 
the ligand (derivatized λmax = 625 nm) was consistent with corresponding results from 
either indole (derivatized λmax = 623 nm) or 5-hydroxyindole (derivatized λmax = 627 
nm).  Thus, the purely spectrophotometric method demonstrated that a highly 
absorbing conjugate of the CYP2A13 ligand could be formed and was successful at 
narrowing the identity of the CYP2A13 ligand.  This characteristic was subsequently 
used for identification of the ligand conjugate on the HPLC phase of HPLC tandem 
MS.   
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Table 3.1:  Comparison of results gathered from indoles tested (ND: not determined) 
 
 
N
H
1
2
34
5
6
7  
(Indole Numbering 
System) 
Spot Test λmax (nm) of 
derivative 
Retention 
Time 
(min) 
MW of derivative 
(experimental 
M+H+) 
indole blue 623 8.7 275 
3-hydroxyindole purple ND ND ND 
4-hydroxyindole blue 652 8.0 291 
5-hydroxyindole blue 627 7.3 291 
6-hydroxyindole blue 632 7.2 291 
tryptophan red 578, 480 ND ND 
oxindole (indolin-2-
one) 
red ND ND ND 
isatin (1H-indole-
2,3-dione) 
orange ND ND ND 
unknown blue 625 8.6 275 
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 From previous literature and the results of the spot test, we hypothesized that 
the reaction that resulted in the conjugates absorbing in the 600-700 nm wavelength 
region was a different regiochemical reaction than the reaction of indole-3-methanol 
reported by Muñoz and coworkers (8).  Muñoz reported the generation of an 
azafulvenium salt from the reaction of indole-3-methanol with DMACA (Figure 3.2 
A).  This reaction occurred at the 2 position on the indole nucleus because the 3 
position was blocked by the substituent.  It has been reported that in the reaction of 
indole and retinal, the 3 position of indole is the most nucleophilic when not blocked 
(9).  Likewise, in the Vilsmeir-Haack formylation of indole, selective electrophilic 
addition to indole is made at the 3 position (10).  The compounds from our set of 
indoles that react with DMACA most rapidly and give spectrophotometric responses 
at the lowest concentrations are those with the unhindered 3 position.  It may be that 
the free 3 position of the studied indoles was the reason for the increased sensitivity 
(proposed reaction in Figure 3.2 B).   
 37 
 
 
Figure 3.2:  Proposed reaction schemes of indole-3-methanol (as proposed in (8), A) 
and unsubstituted indole (B) with p-dimethylaminocinnamaldehyde to form highly 
conjugated chromophores.  
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Standards of DMACA conjugates for 4-hydroxyindole, 5-hydroxyindole, 6-
hydroxyindole, and indole were tested to determine retention times and separability 
with injection concentrations of indoles at 0.2 pmol/µL.  UV/Vis detection at 625nm 
(λmax of conjugate in protein mixture) of 4-hydroxyindole and 6-hydroxyindole 
DMACA conjugates were significantly lower than that of the other two conjugates 
due to their lower molar absorptivity at the detection wavelength.  It was also 
observed that the sample analysis was optimal when analyzed the same day.  Samples 
that were exposed to ambient conditions overnight showed significant decomposition 
of the DMACA conjugate.  The predicted products of DMACA and indole were 
detected as MH+ coinciding with the 625 nm HPLC-UV/Vis peak.  In subsequent 
injections, product ion scans reveal a common fragment at m/z = 158 (Figure 3.3) in 
all derivatives tested. Utilizing multiple reaction monitoring (MRM) targeted MS/MS 
detection with two transitions of 274 and 291 to 158, the HPLC chromatographic 
resolution was preserved with a fast detection cycle line (< 1 s). Figure 3.3 illustrates 
the MRM (A) and HPLC-UV/Vis detection (B) of a standard mixture of DMACA 
conjugates of 5-hydroxyindole and indole.  Adjacent are similar traces of the 
derivative from the CYP2A13/ligand mixture (C and D, respectively).  The MS/MS 
scan of conjugated indole in the standard mixture is presented in E.  DMACA 
conjugation and extraction of the protein/ligand sample presented an HPLC peak with 
a product ion spectrum identical to the standard indole product ion spectrum shown in 
E.   
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               Standard Mixture                     Protein 
    of Indole and 5-Hydroxyindole          Extract   
 
 
Figure 3.3: HPLC-Vis-MS/MS traces from indole standards and protein extract.  A 
mixture of indole and 5-hydroxyindole standard conjugates (200 nM each) detected 
with MS/MS transition of (A) m/z 291 to 158 (from 5-hydroxyindole conjugate) and 
274 to 158 (from indole conjugate), and B 625 nm HPLC trace.  Spectra 
corresponding to A and B but from protein extract are illustrated in C and D, 
respectively.  The MRM transitions were chosen from product ions observed in 
standard indole derivative product ion spectrum E.  The proposed structure and 
identity of major ions of conjugated indole are illustrated in F. (cts = counts, mAU = 
milli-absorbance unis) 
40 
The proposed structure assignment (F) is supported by the common ion at m/z = 158 
between all derivatives and that m/z = 130 for the indole derivative shifts to m/z = 
146 in hydroxyindole samples.  The HPLC-UV/Vis-MS/MS experiment positively 
confirmed the presence of indole in the purified protein/ligand mixture. 
 The information generated by this assay provided the rationale for modeling 
unsubstituted indole into the CYP2A13 active site (Figure 3.4).  When indole is 
modeled in a single orientation so that it directly hydrogen bonds with Asn297 (yellow 
indole in Figure 3.4), a significant amount of electron density remains above the 5-
position of indole.  The analytical examination of the protein samples showed no 
detectable 5-hydroxyindole in the mixture, so it was hypothesized that unsubstituted 
indole may also occupy a second orientation in the active site causing this density.  
The alternate orientation involves indole rotating ~80° from its previous location.  It 
was then modeled such that a water molecule bridges between the indole nitrogen and 
Asn297 (teal indole and small red sphere in Figure 3.4).  The final model of the 
CYP2A13 structure refined to have these two orientations with near equal occupancy 
with small deviations between different molecules in the asymmetric unit of the 
crystalline lattice.   
 
Conclusions: 
While the colorimetric spot test for indole production has been in common use 
in microbiology for years, to our knowledge this is the first account utilizing the 
strongly absorbing chromophore generated in the conjugation as a handle for LC-
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UV/Vis detection with subsequent MS/MS for unambiguous identification of indoles.  
The derivative, while relatively short lived (1/2 day), greatly improved the UV/Vis 
and HPLC detectability by moving the absorbance into the visible region and out of 
small aromatic absorbing region, increasing HPLC selectivity, and enhanced MS 
efficiency for indoles with unhindered 3 positions.  This method of derivatization and 
detection of indoles was successful in confirming the presence of unsubstituted indole 
in the crystallization solution and allowed indole to be modeled into the CYP2A13 
active site.  In the future, the utility of this assay can be used to identify indole 
metabolites generated by CYP2A13. 
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Figure 3.4:  CYP2A13 active site with 2|Fo|-|Fc| electron density map at 1.0 σ (blue 
mesh) and indole modeled in two alternate conformations.  Each alternate 
conformation has a different hydrogen bonding opportunity.  The indole in 
conformation A (yellow indole) is within direct hydrogen bonding distance to Asn297.  
Alternately, indole in conformation B (teal indole) is proposed to interact with Asn297 
through a modeled water molecule (small red sphere). 
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Chapter 4. 
Structure of Cytochrome P450 2E1 in Complex with Indazole 
The experiments described in this chapter have been previously published as: 
Porubsky, P. R., Meneely, K. M., and Scott, E. E. (2008) J Biol Chem 283(48), 
33698-33707.  The atomic coordinates and structure factors of the structure described 
in this chapter have been deposited in the protein data bank (code 3E6I). 
Introduction 
Cytochrome P450 (P450) is a superfamily of enzymes involved in 
monooxygenation of both endogenous and exogenous substrates.  A subset of these 
enzymes, including cytochrome P450 2E1 (CYP2E1), are known for their role in the 
clearance of drugs and other xenobiotics by introducing or unmasking sites for 
subsequent conjugation and elimination from the body.  From a biochemical 
standpoint these enzymes are fascinating for the diversity of substrates each 
xenobiotic-metabolizing P450 can metabolize, yet often with exquisite selectivity in 
the metabolites generated.  Unfortunately, in the process some P450-mediated 
metabolism can produce toxic or carcinogenic products.  Among cytochrome P450 
enzymes, CYP2E1 is particularly notable for this ability and the resulting toxicity (1). 
It is primarily hepatic comprising over 50% of the hepatic cytochrome P450 mRNA 
(2) and 7% of the hepatic cytochrome P450 protein (3).  However, CYP2E1 is also 
expressed at lower levels in a variety of extrahepatic tissues (4), where it is thought to 
play a role in the metabolism of important endogenous molecules.  CYP2E1 levels 
and toxicity varies markedly in response to alcohol consumption (5), diabetes (6), 
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obesity (7), and fasting (8).  Thus, the action of CYP2E1 can have significant 
influence on human health and drug metabolism. 
CYP2E1 has been connected with liver toxicity through two mechanisms: by 
the activation of substrates into reactive metabolites and potentially by generation of 
reactive oxygen species (ROS).  As described in Chapter 1, when substrate binding, 
oxygen binding, and electron delivery are not closely coordinated during catalysis, 
diatomic oxygen can be converted to superoxide or hydrogen peroxide and released 
instead of being used to monooxygenate the substrate. These ROS have been 
implicated in a range of damaging events including lipid peroxidation, protein 
oxidation, and DNA oxidation.  CYP2E1 is considerably more prone to ROS 
production than other cytochrome P450 enzymes (9). For example, evidence shows 
that ethanol consumption substantially increases the levels of CYP2E1 protein and 
the resulting ROS have been suggested as the primary contributors to the negative 
physiological consequences of alcohol-induced liver disease (10).  However studies 
with induction of CYP2E1 or CYP2E1 knockout mice have not detected alterations in 
the in vivo levels of ROS-mediated isoprostanes, a measure of oxidative stress (11). 
Two well-studied drugs that are converted to reactive metabolites by CYP2E1 
are acetaminophen (12,13) and halothane (14).  Acetaminophen is the most widely 
used analgesic in the U.S. (15) and one of the leading causes of fatal poisonings (16).  
Activation of acetaminophen by CYP2E1 into the strongly electrophilic N-acetyl-p-
benzoquinone-imine (NAPQI) is the initial and major step responsible for 
acetaminophen hepatotoxicity.  Halothane is a volatile anesthetic whose use was 
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discontinued due to severe hepatitis induced by CYP2E1 oxidation to trifluoroacetic 
acid chloride (TFAC).  TFAC covalently modifies proteins to create an antigen that 
the body can recognize in later halothane exposures, resulting in severe hepatic 
necrosis known as halothane hepatitis (17).   
 Acetaminophen and halothane are just two clinical representatives of the >70 
low molecular weight (<100 g/mol) substrates that CYP2E1 is known to metabolize.  
These substrates include industrial solvents such as benzene, toluene, aniline, and 
halogenated solvents (18); alcohols such as ethanol (19), glycerol, phenol, and p-
nitrophenol (20); and bicyclic heterocycles such as caffeine (21) and the muscle 
relaxant chlorzoxazone (22).  However CYP2E1 is also known to metabolize 
endogenous fatty acids, including lipids associated with signaling mechanisms such 
as arachidonic acid (23) and epoxyeicosatrienoic acids (24).  The role of CYP2E1 in 
the metabolism of these signaling molecules may be related to its regulation by 
disease states such as obesity (25) and diabetes (26) in rat models.  
 Although structures of several other important drug-metabolizing 
cytochromes P450 have been solved in recent years and a number of CYP2E1 models 
have been proposed, there are no experimental structures for CYP2E1.  Cytochromes 
P450 have similar overall tertiary structures, but differ substantially in the size and 
shape of their active sites and the presence and topology of channels allowing 
substrate entry and metabolite egress, factors that in turn determine substrate 
selectivity in this enzyme superfamily.  In order to better understand the ability of 
CYP2E1 to efficiently bind and metabolize both small molecular weight compounds 
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and fatty acids, the structure of this enzyme was determined by X-ray crystallography 
bound with the small molecular weight inhibitor indazole.  Comparison of CYP2E1 
structures to those of other human P450 isoforms provides insight into the functional 
similarities and differences among the human cytochrome P450 enzymes. 
 
Methods 
 Protein Engineering, Expression, Purification, and Ligand Complexation 
 See Methods (Chapter 2) for the description of protein engineering, 
expression, purification, and formation of the ligand complex. 
 Protein Crystallization, Data Collection, and Structure Determination 
 Crystals were grown by hanging drop vapor diffusion as described in Methods 
(Chapter 2).  The CYP2E1/ indazole complex (50 mg/mL CYP2E1, 5 mM indazole) 
was equilibrated against 0.1 M NaHEPES pH 7.5, 11% iso-propanol, and 6% PEG 
2000 MME. Crystals were immersed in 0.1 M NaHEPES pH 7.5, 10% iso-propanol, 
1.4 M sucrose as a cryoprotectant before being flash cooled in liquid nitrogen for data 
collection.  A single native data set was collected for each complex on beamline 9-2 
at the Stanford Synchrotron Radiation Laboratory (Stanford, CA) with a wavelength 
of 0.979 Å at 100 K.  Data were processed using Mosflm (27) and Scala (28).  The 
CYP2E1/ indazole structure was solved by molecular replacement using the program 
PHASER (29) and a search model consisting of CYP2A13 (PDB 2P85) with non-
identical side chains truncated at the last common atom.  Iterative model building and 
refinement were performed using COOT (30) and REFMAC (31). 
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Structure validation was performed using WHAT-IF (32) and PROCHECK 
(33).  For the indazole bound CYP2E1 structure the Ramachandran plot showed 
89.4% of the amino acid residues in the most favorable region, 9.3% in the additional 
allowed region, 0.8% in the generously allowed region, and 0.5% in the disallowed 
region.  
 Structure Analysis 
 Voids and exit channels were probed using VOIDOO (34)  and CAVER (35) 
as described in Methods (Chapter 2).  Secondary structure was determined using 
DSSP (36).  
  
Results 
 Protein Design and Structure Determination 
Understanding the substrate selectivity of CYP2E1 as it plays roles in drug 
metabolism and both normal and pathophysiology has been hampered by the absence 
of experimental structural information about this enzyme.  In order to facilitate 
structure determination of this integral membrane protein, CYP2E1 was engineered to 
remove the single N-terminal transmembrane helix (residues 3–23) and add a C-
terminal His4 tag, as has been recently used to crystallize other mammalian P450 
enzymes.  The resulting truncated protein is a monotypic membrane protein that can 
be solubilized, purified, and maintained in an active, monodisperse state in the 
presence of detergent.  Absorbance spectra revealed that the purified CYP2E1 was in 
a mixed spin state, suggesting that in solution some CYP2E1 protein molecules have 
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water bound to the sixth coordination site of the heme iron, but in other molecules the 
water is absent and the heme iron is five-coordinate.  Most mammalian P450s are 
water-coordinated in the resting state, but this mixed spin state has previously been 
reported for full-length human CYP2E1, although it has also been isolated as either 
all high spin or all low spin (37-40).  When reconstituted with NADPH-cytochrome 
P450 reductase and cytochrome b5, the truncated, purified CYP2E1 is catalytically 
competent in performing two classic CYP2E1 reactions:  2-hydroxylation of p-
nitrophenol and 6-hydroxylation of chlorzoxazone (data not shown).  Additionally, 
this enzyme has a Kd value for indazole similar to those previously reported for the 
full-length rabbit CYP2E1 (41).  Diffraction data were collected to 2.2 Å on a single 
crystal of CYP2E1 co-crystallized with indazole.  Data collection and refinement 
statistics are described in Table 4.1.  The final CYP2E1/indazole model includes 
residues K31-S493, with the exception of 138-139.  The two unmodeled residues are 
part of a GXG motif in the loop connecting helices C and D and whose flexibility 
likely contributed to disorder.  Coordinates have been deposited in the Protein Data 
Bank (PDB code 3E6I). 
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Table 4.1:  Data collection and refinement statistics. 
 
 Indazole-bound 
Data collection  
Space group P43 
Cell dimensions  
    a, b, c (Å) 71.2, 71.2, 225.8 
    α, β, γ  (°)  90.0, 90.0, 90.0 
Resolution (Å)* 112.51 - 2.20 (2.26 - 2.20) 
Rsym*+ 0.080 (0.338) 
I/σI* 15.5 (3.5) 
Completeness (%)* 99.7 (99.3) 
Redundancy* 5.9 (3.5) 
  
Refinement  
Resolution (Å) 41.78 - 2.20 
No. of reflections 53,342 
Rwork / Rfree 22.0/28.3 
No. of atoms  
    Protein 7,560 
    Ligand 18 
    Heme 86 
    Water 171 
B-factors  
    Protein 39.9 
    Ligand 30.0 
    Heme 31.2 
    Water 35.0 
R.m.s. deviations  
    Bond lengths (Å) 0.013 
    Bond angles (°) 1.62 
*Values in parentheses are for highest-resolution shell. 
+
! 
Rsym = hkl i Ii(hkl) " I(hkl) / hkl i Ii(hkl)####  
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Overall Structure 
The CYP2E1 structure exhibits the canonical P450 fold consisting of 12 major 
α-helices and 4 β-sheets, designated A–L and β1–β4, respectively.  Short intervening 
helices typically found in mammalian membrane P450s are also present and are 
designated by primes or double primes (Figure 4.1 A).  The two CYP2E1 molecules 
present in the asymmetric unit are nearly identical to each other with a root mean 
squared deviation (RMSD) for the Cα atoms of 0.22 Å. When compared to other 
mammalian cytochrome P450 structures in the Protein Data Bank, CYP2E1 has the 
highest structural similarity to human CYP2A13 (PDB 2P85; RMSD 1.00 Å) (Figures 
4.1 B and 4.2) and human CYP2A6 (RMSD 1.03 – 1.05 Å depending on the ligand 
bound to the CYP2A6 structure).   
Active site 
In the CYP2E1 complex with indazole, there is clear electron density for the 
inhibitor in the active site (Figure 4.3).  One nitrogen of indazole forms a coordinate 
covalent bond to the heme iron (N2-Fe, 2.19 Å).  The adjacent indazole nitrogen 
hydrogen bonds with the side chain hydroxyl of T303.  Coordination of indazole to 
the heme iron is consistent with the experimentally observed type II spectral changes 
that suggest nitrogen replaces water in the sixth coordination position of the iron upon 
titration with IND (data not shown).   
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Figure 4.1:  Overall structure of CYP2E1 and overlay with CYP2A13.  (A) Distal 
face of CYP2E1 rainbow colored from N-terminus (blue) to C-terminus (red).  
Helices are labeled using typical P450 nomenclature.  (B) Structural overlay of 
CYP2E1 (blue) and CYP2A13 (green) using secondary-structure matching (42) in 
COOT (30) with a Cα root mean square deviation of 1.00 Å.  All protein structure 
figures generated using PyMOL (43). 
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       1                                                                       50 
2A13dH  MA~~~~~~~~ ~~~~~~~~~~ ~~~~KKTSSK GKLPPGPTPL PFIGNYLQLN  
2E1dH   MA                        KKTSSK GKLPPGPFPL PIIGNLFQLE  
                                                          A' 
 
           51                                                                      100 
  2A13  TEQMYNSLMK ISERYGPVFT IHLGPRRVVV LCGHDAVKEA LVDQAEEFSG  
  2E1   LKNIPKSFTR LAQRFGPVFT LYVGSQRMVV MHGYKAVKEA LLDYKDEFSG  
                A           β1-1         β1-2              B          β1-5 
 
           101                                                                     150 
  2A13  RGEQATFDWL FKGYGVAFSN GERAKQLRRF SIATLRGFGV GKRGIEERIQ  
   2E1  RGDLPAFH-A HRDRGIIFNN GPTWKDIRRF SLTTLRNYGM GKQGNESRIQ 
               B'                     C                     D 
 
           151                                                                     200 
  2A13  EEAGFLIDAL RGTHGANIDP TFFLSRTVSN VISSIVFGDR FDYEDKEFLS  
   2E1  REAHFLLEAL RKTQGQPFDP TFLIGCAPCN VIADILFRKH FDYNDEKFLR 
                                      E                     F 
 
           201                                                                     250 
  2A13  LLRMMLGSFQ FTATSTGQLY EMFSSVMKHL PGPQQQAFKE LQGLEDFIAK  
   2E1  LMYLFNENFH LLSTPWLQLY NNFPSFLHYL PGSHRKVIKN VAEVKEYVSE  
                            F'     G'                  G 
 
           251                                                                     300 
  2A13  KVEHNQRTLD PNSPRDFIDS FLIRMQEEEK NPNTEFYLKN LVMTTLNLFF  
   2E1  RVKEHHQSLD PNCPRDLTDC LLVEMEKEKH SAERLYTMDG ITVTVADLFF 
                               H                       I 
 
           301                                                                     350 
  2A13  AGTETVSTTL RYGFLLLMKH PEVEAKVHEE IDRVIGKNRQ PKFEDRAKMP  
   2E1  AGTETTSTTL RYGLLILMKY PEIEEKLHEE IDRVIGPSRI PAIKDRQEMP 
                                     J                  J'   K 
 
 
           351                                                                     400 
  2A13  YTEAVIHEIQ RFGDMLPMGL AHRVNKDTKF RDFFLPKGTE VFPMLGSVLR  
   2E1  YMDAVVHEIQ RFITLVPSNL PHEATRDTIF RGYLIPKGTV VVPTLDSVLY  
                K               β1-4    β2-1   β2-2     β1-3    K' 
 
           401                                                                     450 
  2A13  DPRFFSNPRD FNPQHFLDKK GQFKKSDAFV PFSIGKRYCF GEGLARMELF  
   2E1  DNQEFPDPEK FKPEHFLNEN GKFKYSDYFK PFSTGKRVCA GEGLARMELF 
                       K”                                 L 
 
    
           451                                                             494 
  2A13  LFFTTIMQNF RFKSPQSPKD IDVSPKHVGF ATIPRNYTMS FLPRHHHH 
   2E1  LLLCAILQHF NLKPLVDPKD IDLSPIHIGF GCIPPRYKLC VIPRSHHHH 
                    β3-3     L'       β4-1   β4-2      β3-2  HHHH 
Figure 4.2:  Sequences and secondary structures of CYP2E1 and CYP2A13 (2P85) as 
determined by DSSP (36).  Boxes and double underline indicate α helices and β 
sheets, respectively.  Italics indicate N- and C-terminal modifications of CYP2E1 and 
CYP2A13 for expression, purification, and crystallization. 
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Figure 4.3: Heme and ligand electron density maps.  Electron density shown as 
composite omit σA-weighted 2FO− FC map contoured at 1.0 σ around the heme 
and indazole. 
56 
In complex with indazole the overall active site cavity of CYP2E1 is small, 
globular, and highly hydrophobic (Figure 4.4 A).  The active site volume was 190 Å3, 
consistent with the small molecular weight of most CYP2E1 substrates.  The amino 
acid residues that line the active site cavity include A299 and T303 on successive 
turns of the I helix and which bracket the active site.  The opposing face of the active 
site is formed by the intersection of residues in and near the B' helix (F106, I115, and 
F116), the loop between K and β1-4 (V364 and L368) and the β4-1/β4-2 turn (F478) 
(Figure 4.4 A).  A total of five phenylalanine residues (F106, F116, F207, F298, and 
F478) form the face opposite the heme, many separating the active site from two 
other enclosed voids. 
Second Void Adjacent to Active Site 
A second enclosed cavity is found adjacent to the active site cavity (Figure 
4.4).  This second isolated cavity has a volume of 77 Å3, is located between the I, F, 
G, and B' helices, and is not present in related P450 enzymes.  In CYP2A13 and 
CYP1A2 a small portion of this area is part of the active site, while protein atoms 
occupy this area in CYP2A6. The active site and this adjacent cavity are separated by 
the approach of the side chains of F106 and F298.  The narrowest constriction 
between the two cavities is a distance of 3.8 Å between the atom centers in these two 
aromatic side chains (Figure 4.4 B), leaving a gap of 0.4 Å between the van der 
Waals surfaces.  Residues lining this additional cavity are H109, L202, F203, N206, 
V239, V242, K243, A294, and D295. 
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Figure 4.4: Active site of CYP2E1.  Wall-eyed stereo views of the CYP2E1 active 
site illustrating constrictions between the ligand-containing active site, the small 
distal void, and the substrate access channel.  Cavities are shown in grey mesh.  
Substrate access channel is omitted from panel (A) and F-helix omitted from panel 
(B) for clarity.  Helices and loops colored as indicated:  B' helix and adjacent loop 
(blue); F helix (orange); G helix (purple); I helix (yellow); loop between K and β1-4 
(green); β4-1/β4-2 turn (pink). 
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Access Channel 
CYP2E1 also has a broad channel originating adjacent to the active site 
opposite the I helix (Figure 4.4 B), and ultimately extending to the surface of the 
protein.  The access channel contains a number of well-defined water molecules.  The 
channel is not linear, but instead has several side channels toward either side of the F 
helix, though these do not reach the surface.  On the protein surface, the single 
channel opening is surrounded by residues in the loop prior to the B' helix, the loop 
between the F' and G' helices, and residues from the β1 system (Figure 4.4 A).  At its 
interior terminus, the access channel is separated from the active site cavity primarily 
by F478 with flanking residues including L103 and active site residues V364 and 
L368 (Figure 4.4 B).  The narrowest constriction is between F478 at the tip of the β4 
system and L103 that immediately precedes the B' helix (3.7 Å between atom centers 
leaving a gap of 0.6 Å between van der Waals surfaces).  Slight rotation of F478 
would easily allow direct communication between the active site and this channel to 
allow ligand or solvent access and egress.  There is space to either side of F478 for 
such a rotation in the access channel (Figure 4.5 B). 
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Figure 4.5:  CYP2E1 access channel location  (A) Access channel, active site, and 
extra volume are shown in black mesh.  Protein regions bordering the access channel 
entrance are colored in green.  (B) Active site void connectivity using a 1.4 Å radius 
probe (black mesh) versus a 0.9 Å radius probe (green mesh).  (C) Most accessible 
exit path calculated by CAVER (35) is shown as light grey spheres.  Residues 
proposed to interact with a fatty acid carboxylate are shown in yellow. 
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Discussion 
 Crystallization 
 The crystallization of CYP2E1 had been pursued for several years using a 
variety of ligands but no crystals had been obtained.  All of these attempts utilized a 
buffer system that had been used in the crystallization of all previously published 
mammalian CYPs.  This buffer system was high ionic strength (50 mM KPi, 500 mM 
NaCl) and included glycerol (20%) as a stabilizing agent.  The two major 
breakthroughs in the CYP2E1 crystallization were the use of indazole as a high 
affinity ligand and altering the protein buffer system to low ionic strength (100 mM 
KPi) and exchanging the stabilizing agent for sucrose (0.5 M).  This ligand and buffer 
system appears to help stabilize CYP2E1 as observed in facilitating crystal formation 
and in helping maintain the characteristic P450 spectrum that can be alter when the 
protein is not stabilized.  This approach may be useful in crystallizing other difficult 
to crystallize CYPs. 
Active Site 
The size of the immediate active site (190 Å3) is the smallest observed for a 
human cytochrome P450 enzyme (Figure 4.6 A) and is consistent with the low 
molecular weight of many CYP2E1 substrates.  CYP2E1-metabolized drugs like the 
analgesic acetaminophen (MW 151), the muscle relaxant chlorzoxazone (MW 170), 
the volatile anesthetic sevoflurane (MW 200), and ethanol (MW 46) could all be 
easily accommodated within this volume, as well as the marker substrate 4-
nitrophenol (MW 140).  In fact, CYP2E1 has been called a "molecular sieve" (44)  
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Figure 4.6:  Active site and access channel comparisons for human xenobiotic-
metabolizing cytochrome P450 enzymes.  (A) CYP2E1, (B) CYP2A6 (PDB 1Z10), 
(C) CYP2A13 (PDB 2P85), (D) CYP1A2 (PDB 2HI4), (E) CYP2C9 (PDB 1OG2), 
(F) CYP2C8 (PDB 1PQ2), (G) CYP2D6 (PDB 2F9Q), and (H) CYP3A4 (PDB 
1TQN).  The volumes were calculated by VOIDOO as described in Methods (Chapter 
2). 
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with respect to its preference for small substrates.  Although other isozymes may act 
on these same substrates with a higher Vmax, CYP2E1 is frequently the low Km or high 
affinity enzyme.  
Cytochromes P450 2A6, 2A13, and 1A2 also have relatively small active site 
cavities and typical substrates.  The volumes of the CYP2A13 and CYP2A6 cavities 
are 304 Å3 and 230 Å3, respectively, while the CYP1A2 active site is 406 Å3 (Figure 
4.6 B-D).  Comparison of the CYP2E1 active site cavity with those of CYP2A6 and 
CYP2A13 indicates that one of the reasons for the decrease in the active site volume 
is due to the identity of the residue at position 115, which is directed into the active 
site.  CYP2E1 has Ile at this position, while 2A6 and 2A13 have Val and Ala, 
respectively.  Several residues that line the cavity of CYP2A13 are not part of the 
CYP2E1 active site cavity because other active site residues screen them.  For 
example, in CYP2E1 H109 and A294 are cut off from the active site cavity by F106 
and F116; D295 is obscured from the active site by I115; and P363 is positioned 
behind V364.   
  The CYP2E1 active site cavity is most open above the heme D pyrrole ring.  
This is in general agreement with heme modification studies in which the aryl group 
of aryl-heme iron complexes predominantly modifies the D ring of CYP2E1 (45,46).  
In addition, the active site is largely nonpolar with a number of bordering 
phenylalanine residues that might interact with aromatic substrates.  This is consistent 
with the characterization of many CYP2E1 substrates as neutral compounds with 
relatively high logP values, many often containing an aromatic ring.   
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The only polar side chain lining the active site is the highly conserved T303.  
This residue orients the indazole in the CYP2E1 active site through hydrogen bonding 
to the side chain hydroxyl.  The mutation of T303 in rabbit CYP2E1 to serine, valine, 
or alanine has shown varying effects on CYP2E1 activity.  The mutation T303V is 
less active in fatty acid hydroxylation than wild type CYP2E1 but retains the fatty 
acid regioselectivity (47).  CYP2E1 T303S also has decreased activity in fatty acid 
hydroxylation, but additionally loses regioselectivity, suggesting the methyl group is 
important in orienting the fatty acids in the active site (47,48).  Similarly, the 
CYP2E1 T303A mutation alters the metabolism of isothiocyanates (49).  This residue 
may play a similar role in the positioning of smaller substrates.  Evidence suggests 
that this conserved T303 plays a role in proton delivery to the active site in other 
P450 enzymes (50-52) and in CYP2E1 (53), but unfortunately no direct studies on the 
uncoupling of the CYP2E1 T303 mutants have been published. 
Several residues in the active site of CYP2E1 have been mutated to the 
corresponding CYP2B6 residues (54).  The CYP2E1 mutants V364L, L368V, and 
F478V had increased 7-ethoxy-4-trifluoromethylcoumarin (7-EFC) deethylation 
activity, but lower p-nitrophenol (PNP) hydroxylation activity than wild type 
CYP2E1, indicating these residues are important for CYP2E1 specificity.  In the 
CYP2E1 structure, these three residues line the active site and may play direct roles 
in positioning these substrates by recontouring the active site volume.  These 
substitutions made in CYP2E1 are likely to change the active site steric bulk to be 
less compatible with orientation of p-nitrophenol for hydroxylation of the phenol ring 
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than O-dealkylation of ethoxycoumarin.  In CYP2B6, the combination of substitution 
of a larger residue at 364 and a smaller residue at 368 may complement each other so 
that this part of the active site void volume is shifted toward residue 368 (Figure 4.4 
B).  However, V364, L368, and F478 also form part of the constriction between the 
active site cavity and the access channel and therefore could also play roles in 
substrate access.  Substitution of F478 to valine would likely eliminate the 
constriction between the active site and the access channel (Figure 4.4 B).  The 
CYP2E1 mutant L210I also showed less PNP hydroxylation activity than wild type 
but similar 7-EFC deethylation activities.  The residue L210 is not directly part of the 
active site cavity wall, but rather packs against the aromatic ring of F478 between the 
access channel and the active site.  Thus, altering the amino acid at this position to an 
isoleucine could have indirect effects on substrate access or on ligand positioning in 
the active site. 
 Access Channel 
The large channel observed in CYP2E1 nearly connects the protein exterior to 
the active site void, barring only a constriction formed primarily by the side chain of 
F478.  The narrowest distance between protein carbon atom centers (L103 and F478) 
is 3.7 Å.  There is space on both sides of the F478 side chain into which this aromatic 
ring could rotate to open up a connection between the two spaces.  Even without 
moving F478, using a smaller spherical probe to map the cavities in VOIDOO shows 
connections both between the active site and the access channel on either side of F478 
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and between the active site and the second enclosed void above the I helix (Figure 4.5 
B). 
The program CAVER was used to find the most accessible path from the 
active site to the surface of the protein.  The most accessible exit/entrance path leaves 
the active site between L103 and F478 and then follows the VOIDOO access channel 
to the surface of the protein (Figure 4.5 C).  When searching for multiple routes out of 
the protein, the top four such paths all described the same basic route, transiting from 
the active site to the access channel on one side or the other of F478. 
The immediate 190 Å3 active site is not large enough to accommodate the C10-
C20 fatty acids that CYP2E1 is known to metabolize.  Saturated C12-C18 fatty acids 
are hydroxylated only at the ω-1 position, with the highest turnover observed for 
lauric acid (12:0) (55).  Additionally, if the carboxylate of palmitic acid (16:0) is 
methylated, no metabolism occurs (55).  These results suggest that when the 
penultimate alkyl carbon is positioned in the active site for hydroxylation, the 
carboxylate forms critical interactions with residues 11-15 carbon bond lengths away.  
The CYP2E1 primary active site is obviously too small to contain the fatty acid, but if 
the side chain of F478 was rotated slightly, the fatty acid hydrocarbon chain could 
extend into the substrate access channel where the side chain nitrogens of Q216 and 
N219 are at the appropriate distance to hydrogen bond with the carboxylate (Figures 
4.5 C and 4.7).  The side chain of N220 lines the access channel slightly farther away 
from the active site and might facilitate binding of longer chain fatty acids.  All three 
of these proposed carboxylate-binding residues are completely conserved in CYP2E1  
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Figure 4.7:  Lauric acid structure overlaid on CYP2E1, demonstrating the distance 
from the active site to the QxxNN access channel residues proposed to bind the 
carboxylate of fatty acid substrates.  In this example the manually docked lauric acid 
is interacting with Q216 and N219 and the subterminal carbon is in position for the 
experimentally observed ω-1 hydroxylation. 
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proteins from different species, forming a QxxNN motif.  Additionally, at the level of 
these polar putative COOH binding residues there is also a large hydrophobic side 
pocket in the access channel, which might also accommodate parts of the longer chain 
fatty acids in a more compact, rather than extended, conformation.  This proposed  
orientation is similar to the orientation of fatty acid analogs bound in the structure of 
BM3, a P450 from Bacillus megaterium (56). 
CYP2E1 metabolizes the unsaturated fatty acids arachidonic acid and linoleic 
acid at the terminal or subterminal positions (23), but also forms epoxides from 
arachidonic acid (14,15-, 11,12- and 8,9- EET (23)) and linoleic acid (9,10- and 
12,13- (57)).  In the case of arachidonic acid omega-1 hydroxylation, the carboxylate 
could even bind to Q75 at the opening of the channel, which would still allow 
extension of the ω-1 carbon over the heme iron (Figure 4.8).  However, in order to 
position the central carbons of arachidonate for the observed epoxide metabolites, the 
fatty acid would have to penetrate farther into the active site.  If the hydrophobic 
F298 and F106 side chains that form the constriction between the main active site and 
the "extra" void were also slightly repositioned, the terminus of the alkyl chain could 
fit into this "extra" space, while the mid-region of the fatty acid could be positioned 
over the iron for epoxide formation, and the carboxyl group could interact with the 
putative carboxylate-binding QxxNN residues in the access channel (Figure 4.8).  
This would require a significant bend in the fatty acid chain, which would be 
consistent with the structure of unsaturated cis fatty acids.  Flash photolysis has 
shown that arachidonic acid can abolish CO dissociation from the heme, suggesting  
68 
 
Figure 4.8:  Arachidonic acid structures overlaid with CYP2E1.  Arachidonic acid 
manually docked into CYP2E1 in conformations consistent with ω-1 hydroxylation 
(blue carbons) or 11,12-epoxidation (tan/orange carbons).  In this figure the 
carboxylate was positioned to interact with Q216 and N219 (for epoxidation) or with 
Q75 and backbone nitrogen of D102 (for omega-1 hydroxylation).  The tan and dark 
blue colored atoms of arachidonic acid indicate the unsaturated positions in the two 
different binding modes.  
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that arachidonic acid binding may "plug" up CO exit (58).  This physical 
interpretation of fatty acid binding is consistent with both the observed fatty acid 
metabolites and the CYP2E1 voids, but should be further investigated by determining 
the structures of CYP2E1/fatty acid complexes. 
Though the human CYP2A enzymes 2A13 and 2A6 are most structurally 
similar to CYP2E1, neither of them have a substrate access channel in the structures 
determined to date.  Compared to the CYP2A enzymes, the secondary structural 
elements of CYP2E1 are overlaid closely throughout the core of the protein, with 
seemingly subtle shifts localized in one quadrant of the protein consisting of the F' 
and G' helices, the B' helix and its adjacent loops, and the N-terminus of the C helix 
(Figure 4.1 B).  However, these structural units partially frame the opening of the 
access channel, along with residues from the β1 system.  The CYP2E1 B' helix is a 
310 helix and is shorter than in CYP2A13 by one residue due to the deletion of a 
tryptophan that is present in CYP2A13 sequence (W109).  Both the B' and G helices 
are slightly shifted toward each other, and in combination with small shifts in the F' 
and G' helices, create the CYP2E1 access channel.  However, a variety of access 
channels have been shown in other mammalian cytochromes and obviously the 
substrates must penetrate to the active site and metabolites must diffuse out (Figure 
4.5).  CYP2C8 has two access channels, one on each side of the B' helix (59).  The 
channel in CYP2C9 exits between helices F and I and the C-terminal β4 sheet system 
(37).  CYP2D6 has the same hydrophilic access channel as CYP2C9 and a second 
putative channel exiting between the G and I helices (60).  CYP3A4 contains three 
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access channels, a channel in the same area as CYP2E1, a second channel through the 
middle of the B' loop, and a third in the same position as CYP2C9 (61,62). 
Location of Naturally Occurring Polymorphisms 
 By comparison with other cytochromes P450, CYP2E1 is fairly highly 
conserved across species, which has been attributed to its physiological roles.  In 
humans, only three nonsynonymous polymorphisms have been reported for human 
CYP2E1:  R76H, V179I, and V389I (http://www.cypalleles.ki.se).  Mutations at 
positions V179 and V389 do not impact enzymatic activity (63,64) and are buried in 
the CYP2E1 structure indicating no direct involvement in catalysis.  However, R76H 
showed similar mRNA levels to the wild type protein, but only ~30% of the protein 
levels (by western blot analysis), suggesting decreased translation or protein 
stabilization.  R76 is part of the β1-2 structural unit, but is located on the surface with 
the side chain oriented toward solvent. 
 Importance of B´ Helix 
Residues flanking and in the B' helix play key roles in forming the opening of 
the substrate access channel, forming part of the constriction between the access 
channel and the active site, serving to define the active site, forming part of the 
constriction between the active site and the second enclosed volume above the active 
site, and also forming part of the wall of this latter void.  The B' region of the protein 
has few interactions with the remainder of the protein; most interactions are within 
the B' helix unit. Significant interactions between the B' helix and the remainder of 
the protein involve only H109 and R112.  The H109 imidazole nitrogen hydrogen 
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bonds to the side chain of D295 in the I helix.  Additionally, in molecule A a water 
molecule resides in this second pocket and is the intermediate link in a hydrogen 
bonding network between the side chain of H109 in the B' helix on one side of the 
void and both the carbonyl of V239 and the backbone nitrogen of K243 in the G helix 
on the opposite side of the void.  In a second interaction R112 hydrogen bonds with 
the side chain of D287 in the I helix.  In other cytochromes P450 the B' helix adopts a 
number of different conformations and may exhibit flexibility in response to various 
ligands.  Thus, residues in this region and their interactions may be critical for protein 
stability and encapsulating the active site. 
 Interactions with Electron Delivery Partners NADPH-cytochrome 
P450 Reductase and Cytochrome b5 
Analysis of the electrostatic surface of CYP2E1 shows a prominent positively 
charged “bowl” on the proximal side of the enzyme (Figure 4.9).  This region is 
proposed to interact with negatively charged regions of both redox partners:  
NADPH-cytochrome P450 reductase and cytochrome b5.  Multiple roles have been 
proposed for cytochrome b5 in P450-mediated metabolism, including delivering to 
P450 the second electron required for catalysis and/or stabilization of P450 in support 
of catalysis.  Cytochrome b5 addition strongly stimulates CYP2E1 metabolism, ~12-
fold for p-nitrophenol (65), 25-fold for acetaminophen (66), 67-fold for 7-
ethoxycoumarin (67), and 270-fold for aniline (68).  Although for many P450 
proteins stimulation of metabolism can be observed upon addition of either 
cytochrome b5 or apo cytochrome b5 (lacking the heme and therefore unable to do  
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Figure 4.9:  Electrostatic surface of CYP2E1.  Electrostatic surface of CYP2E1 as 
calculated by APBS (70) showing the positively charged surface proposed  to be the 
cytochrome b5/NADPH-cytochome P450 reductase binding site.  Arrows marking the 
location of helices are oriented along the long axes of helices to aid in spatial 
orientation.  Heme shown as green spheres.  
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electron transfer), apo cytochrome b5 cannot replace holo cytochrome b5 in CYP2E1 
catalysis, suggesting a role in electron transfer (67).  The putative protein interface 
between CYP2E1 and cytochrome b5 has been explored by cross-linking and site-
directed mutagenesis (69).  These studies identified two cross-links:  between K428 
in CYP2E1 and D53 in cytochrome b5 and between K434 in CYP2E1 and E56 in 
cytochrome b5.  The proposed interaction surface consists of the CYP2E1 meander, 
β-bulge, C, L, and J' helices on the proximal side of the protein and that binds 
cytochrome b5 with its heme perpendicular to the CYP2E1 heme.  However, the 
K428 and K434 residues are 14 Å apart on the CYP2E1 structure while the proposed 
corresponding residues on cytochrome b5 (D53 and E56) are only ~3.4 Å apart (PDB 
1JEX).  Of the nine total intermolecular electrostatic interactions proposed by 
docking (69), only one (R344) is buried in the CYP2E1 structure, while the remainder 
are surface exposed and do contribute to the positively charged bowl on the proximal 
surface.   
Uncoupling and the production of Reactive Oxygen Species 
Very little is known of the structural basis for the propensity of CYP2E1 to 
produce ROS.  In general, reactive oxygen species are generated during P450 
catalysis when either the ferrous oxy species decays to produce superoxide or the 
hydroperoxy form is protonated to release hydrogen peroxide.  Collapse of these 
species could occur if electron or proton delivery is delayed or if the substrate is not 
positioned for attack.  It has been proposed that during uncoupling, the substrate 
could migrate away from the heme and the activated oxygen thus allowing the 
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oxygen to react in other ways (68).  In CYP2E1, transient connections between the 
active site and the other voids in the protein might facilitate substrate movement away 
from the heme after initial binding.  Similarly, the presence of water molecules in the 
CYP2E1 access channel, and the connections between the active site and the access 
channel may also allow water ready access to the active site.  In the resting enzyme, 
facile movement of solvent into and out of the active site may result in the mixed spin 
state observed for CYP2E1.  This increase in high spin character, which in other 
P450s has shown a raising of redox potential (70), may then facilitate the generation 
of ROS.  Finally, the particularly unstable nature of the CYP2E1 enzyme may also 
contribute to uncoupled substrate binding and catalysis.  The magnitude and 
implications of CYP2E1-generated ROS in human disease remain to be elucidated. 
 
Conclusions 
 In summary, this structure has suggested the structural properties that allow 
for the metabolism of the seemingly divergent substrate classes metabolized by 
CYP2E1:  small molecular weight compounds sequestered within a small active site 
and endogenous fatty acids binding with the carboxylate end extending into the 
access channel.  Additional CYP2E1 structures in complex with substrates or fatty 
acids should be pursued to validate and determine the details of these binding modes.  
Finally, further studies will be required to understand the propensity of CYP2E1 to 
generate reactive oxygen species. 
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Chapter 5. 
Structure of CYP2E1 Bound with the Fatty Acid Analog,  
ω-Imidazolyl-decanoic acid 
The atomic coordinates and structure factors of the structure described in this chapter 
have been deposited in the protein data bank (code 3GPH). 
Introduction 
 Cytochrome P450 (CYP) is a superfamily of heme-containing proteins that 
catalyze the monooxygenation of a wide variety of substrates.  One substrate class of 
CYP is fatty acids.  The metabolism of fatty acids by CYP has been proposed to be 
important in maintaining homeostasis of fatty acid levels.  This may be especially 
important in the metabolism of mid-range length fatty acids liberated from the 
peroxisomal and mitochondrial β-oxidation pathway (1).  The reactions known to be 
catalyzed by CYP are the ω-hydroxylation or (ω-1)-hydroxylation of saturated fatty 
acids and epoxidation of the alkenes of unsaturated fatty acids.  One CYP known to 
metabolize fatty acids in addition to the oxidation of xenobiotics is CYP2E1. 
There is a great wealth of biochemical information about CYP metabolism 
and binding of fatty acids but little structural information to date.  The structural 
information currently in hand is for the P450 domain of the fatty acid hydroxylase of 
Bacillus megaterium (P450BM3) bound to either N-palmitoylglycine (2), 
palmitoleate (to a mutant enzyme) (3), or N-(10-imidazolyldodecanoyl)-L-leucine (4).  
In the first two cases the structures show protein/fatty acid complexes in 
conformational states that would not be the catalytic form (the ligands are too far 
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from the heme).  In the case of the imidazole-based compound, the imidazole end of 
the fatty acid analog is coordinate covalently bound to the heme iron, locking it in 
place.  In mammalian systems there are no crystal structures with fatty acids bound in 
the active site of the CYP.  Biochemical data to date has given insights into distances 
between the heme and hydrogen bond donors that would presumably interact with the 
carboxylate end of fatty acids, but the identity of those donors remains elusive.   
 Heme-binding fatty acid analogs similar to N-(10-imidazolyldodecanoyl)-L-
leucine were originally designed in the lab of Dr. Robert Hanzlik for the inhibition of 
lauric acid ω-hydroxylation by CYP4A1 (5-8).  Many “Lewis base” type functional 
groups were screened with the most effective heme-binding analogs being ω-
imidazolyl fatty acid analogs (8).  These compounds were high affinity and gave a 
characteristic spectral shift, indicative of direct nitrogen binding to the heme iron.  
Though CYP2E1 metabolizes fatty acids with chain lengths from C9 (9) to C20 (10), 
the fatty acid metabolized at the highest rate for both CYP4A1 and CYP2E1 is lauric 
acid.  This suggests that the ligands designed to probe the CYP4A1 active site might 
also bind to CYP2E1.   
Recently, the structure of CYP2E1 has been solved and a fatty acid binding 
site proposed that involves the residues Q216, N219, or N220 acting as hydrogen 
bond donors to the carboxylate of fatty acids (see Chapter 4, or (11)). However, 
further work was needed to confirm or disconfirm the identity of the residues 
involved in fatty acid binding.  Initially two approaches were pursued to answer this 
problem including mutagenesis of the proposed residues and X-ray crystal structures 
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of CYP2E1 bound with a fatty acid analog.  Mutants were generated by site-direct 
mutagenesis at the proposed locations, mutating the polar amino acids to either 
leucine or alanine to remove H-bonding or H-bonding and bulk, respectively.  
Unfortunately, inconsistent results were obtained from mutated purified proteins with 
regard to spectral characteristics indicating the ligand bound state, as well as the 
presence of inactive protein (P420).  To accomplish the task of understanding fatty 
acid binding, ω-imidazolyl-fatty acid analogs were generated, binding affinities were 
determined, and a cocrystal structure of CYP2E1 solved bound to one of these fatty 
acid analogs, ω-imidazolyl-decanoic acid.  This work identified a fatty acid 
carboxylate binding mode distinct from that proposed based on the previous structure. 
Methods 
Ligand Synthesis 
The synthesis of ω-imidazolyl-hexanoic acid, ω-imidazolyl-octanoic acid, ω-
imidazolyl-decanoic acid, and ω-imidazolyl-dodecanoic acid was performed as 
previously described (5,8) with the following modifications.  Methylation of the 
bromo-fatty acids was performed using thionyl chloride and methanol rather than 
diazomethane.  Purification of ω-imidazolyl-hexanoic acid, ω-imidazolyl-octanoic 
acid, and ω-imidazolyl-decanoic acid was performed using anion exchange (Dowex 
1X8 200, formate counter ion (12)) rather than cation exchange. Finally, purification 
of ω-imidazolyl-dodecanoic acid was performed by crystallization as the lithium salt. 
Spectral Binding Titrations 
 See Methods (Chapter 2) for the elaboration of spectral binding titrations. 
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Protein Engineering, Expression, Purification, and Ligand Complexation 
 See Methods (Chapter 2) for the description of protein engineering, 
expression, purification, and formation of the ligand complex. 
Protein Crystallization, Data Collection, and Structure Determination 
Crystals were grown by hanging drop vapor diffusion as described in Methods 
(Chapter 2).  The CYP2E1/ω-imidazolyl-decanoic acid complex (0.91 mM CYP2E1, 
25 mM ω-imidazolyl-decanoic acid) was equilibrated against 0.1 M NaHEPES pH 
7.5, 5% iso-propanol, and 20% PEG 2000 MME.  Crystallization drops were initially 
seeded with microcrystals (13) of the CYP2E1/indazole complex to initiate nucleation 
of CYP2E1/ω-imidazolyl-decanoic acid crystals.  In order to ensure crystal 
homogeneity and absence of indazole, portions of the resulting crystals were used to 
serially seed fresh crystallization drops.  Crystals were immersed in 0.1 M NaHEPES 
pH 7.5, 5% iso-propanol, 30% PEG 2000 MME as a cryoprotectant before being flash 
cooled in liquid nitrogen for data collection.  A single native data set was collected on 
beamline 17-BM at the Advanced Photon Source (Argonne, IL) with a wavelength of 
1.00 Å at 100 K.  Data was processed using DENZO (14) and SCALEPACK (15).  
The CYP2E1/ω-imidazoyl-decanoic acid structure was solved by molecular 
replacement using the program PHASER (16) with a search model consisting of 
CYP2E1/indazole (PDB 3E6I). Iterative model building and refinement were 
performed using COOT (17) and REFMAC (18). 
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 Structure validation was performed using WHAT-IF (19) and PROCHECK 
(20). The Ramachandran plot showed 86.5% of the amino acid residues in the most 
favorable region, 12.1% in the additional allowed region, 0.9% in the generously 
allowed region, and 0.5% in the disallowed region.  The residues in the disallowed 
region are I41 (molecule A and B), R379 (molecule A only), and Q141 (molecule A 
only).   I41 and R379 were also in the disallowed region in the indazole-bound 
structure. 
 Structure Analysis 
Voids and exit channels were probed using VOIDOO (21)  and CAVER (22) 
as described in Methods (Chapter 2). 
Results 
 Synthesis and Ligand Binding 
 ω-Imidazolyl-fatty acid analogs were prepared essentially as described (5,8) 
with even chain lengths from C6 (ω-imidazolyl-hexanoic acid) to C12 (ω-imidazolyl-
dodecanoic acid).  Only the simple modifications described in the methods were 
made to the synthesis, largely to avoid the use of diazomethane (Scheme 5.1).  The 
spectral binding affinities of fatty acid analogs are listed in Table 5.1.  Upon binding 
these compounds cause the heme soret peak to shift from a split peak at 390 nm and 
414 nm to a single peak at 424 nm characteristic of a Type II ligand (nitrogen bound 
directly to the heme iron).  The ligand with the highest affinity for CYP2E1 is ω-
imidazolyl-dodecanoic acid with a KD of 2 µM. Spectral binding affinities decrease 
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Scheme 5.1: Synthesis of ω-imidazolyl-fatty acid analogs 
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Table 5.1:  Ligand binding data.  Duplicate lines for each compound corresponds to 
separate titrations, which are averaged in the last column. 
Ligand ClogP# KD (µM) Δ Amax R2 + Average 
KD (µM) 
No Shift*   
N
N
OH
O
 
0.69 
No Shift*   
 
 
21 0.011 0.97 
N
N
OH
O
 
1.7 
21 0.018 0.97 
 
21 
  8.0 0.016 0.98 
N
N
OH
O
 
2.8 
10. 0.029 0.98 
 
  9.0 
  1.8 0.022 0.96 
N
N
OH
O
 
3.7 
  1.9 0.021 0.97 
 
  1.8 
*No shift:  No spectral shift observed at ligand concentration up to 230 µM ligand. 
+R2:  Residual for fit to 
! 
"# =
"#
max
$ ligand[ ]
KD + ligand[ ]
. 
#ClogP: calculated log of the octanol / water partitioning coefficient. 
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with shorter chain lengths for the analogs examined with ω-imidazolyl-hexanoic acid 
exhibiting no observable binding up to 230 µM.   
Structure Determination and Overall Fold 
The cocrystal structure of CYP2E1/ω-imidazolyl-decanoic acid was solved at 
2.7 Å using the CYP2E1/indazole (PDB 3E6I) structure as the search model.  The 
structure was refined to give the final statistics shown in Table 5.2.  The final model 
was very similar to that of CYP2E1/indazole with a R.M.S.D. of Cα atoms of 0.35 Å 
(using secondary structure matching (23)).  As observed in the CYP2E1/indazole 
structure, the Gly-X-Gly residues 138-139 were omitted from the final model due to 
weak electron density.  With this exception the model encompasses residue 31 
through 493. 
Ligand binding interactions 
 The electron density (2FO−FC map shown in Figure 5.1) of ω-
imidazolyl-decanoic acid bound in the active site of CYP2E1 is continuous from the     
heme-binding imidazole to the carboxylate.  The carboxylate interacts with the side 
chain of N206 in the active site of both molecules in the asymmetric unit with 
hydrogen bond distances of 2.5 Å in molecule A and 3.3 Å in molecule B.  On the 
imidazole end of the molecule the non-alkylated imidazole nitrogen is coordinate 
covalently bound to the heme iron with distances of 2.4 Å in molecule A and 2.3 Å in 
molecule B.  This is consistent with nitrogen-iron distances observed for other CYP 
enzymes in complex with Type II ligands.  The alkylated imidazole nitrogen lies 
outside of hydrogen bonding distance from the CYP2E1 hydrogen bond  
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Table 5.2:  Data collection and refinement statistics. 
 ω-imidazolyl-decanoic 
acid-bound 
Data collection  
Space group P43 
Cell dimensions  
    a, b, c (Å) 70.7, 70.7, 222.8 
    α, β, γ  (°)  90.0, 90.0, 90.0 
Resolution (Å)* 50.00 – 2.70 (2.80-2.70) 
Rmerge* 0.104 (0.457) 
%  > 3 σ (I)* 76.5  (48.5) 
Completeness (%)* 95.4 (93.4) 
Redundancy* 6.7 (6.3) 
  
Refinement  
Resolution (Å) 31.31 – 2.70 
No. reflections 27040 
Rwork / Rfree 21.2 / 28.3 
No. atoms  
    Protein 7536 
    Ligand 34 
    Heme 86 
    Water 25 
B-factors  
    Protein 28.9 
    Ligand 29.9 
    Heme 24.8 
    Water 14.8 
R.m.s. deviations  
    Bond lengths (Å) 0.019 
    Bond angles (°) 1.909 
*Values in parentheses are for highest-resolution shell 
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Figure 5.1: Heme and ligand electron density maps shown in wall-eyed stereo view.  
Electron density shown as composite omit σA-weighted 2FO− FC map contoured 
at 1.0 σ around the heme and ω-imidazolyl-decanoic acid. 
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donor/acceptor, T303.  The lack of H-bonding by this imidazole nitrogen is logical 
since the lone pair electrons of the alkylated imidazole nitrogen would be delocalized 
in the aromatic ring and thus decrease its affinity for accepting hydrogen bonds. 
Active site  
 The active site of CYP2E1 makes only subtle changes in order to 
accommodate the fatty acid analog, ω-imidazolyl-decanoic acid.  In comparing the 
CYP2E1 structure bound with indazole or with ω-imidazolyl-decanoic acid (Figure 
5.2) the largest change is the position of F298.  This side chain forms a barrier 
between the active site void and small additional void in the indazole-bound structure.  
In the ω-imidazolyl-decanoic acid-bound structure, this side chain rotates 
approximately 60°, making the two voids connect and allowing the analog to extend 
into the space between the B′, and F-helices beneath the G-helix.  It interacts with 
N206, which has not altered positions between structures.  Several other residues also 
make minor shifts to acclimate to ω-imidazolyl-decanoic acid, including F106, F207, 
and F478.  These shifts appear to be either in adjustment to the rotation of F298 or the 
presence of the hydrophobic methylene chain of the ligand.  T303 also shifts from its 
position in the indazole-bound structure.  The shifting of side chains in the fatty acid 
analog-bound structure caused an increase in active site volume from 190 Å3 
(indazole-bound) to 445 Å3  (ω-imidazolyl-decanoic acid-bound) (Figure 5.3). 
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Figure 5.2:  Changes in CYP2E1 active site residues in alternate ligand-bound 
structures shown in wall-eyed stereo view.  Amino acid side chains within 5 Å of ω-
imidazolyl-decanoic acid are shown.  The ω-imidazolyl-decanoic acid-bound 
structure is shown in magenta while the indazole-bound structure is shown in yellow. 
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Figure 5.3:  Comparison of CYP2E1 active site voids when bound with ω-imidazolyl-
decanoic acid (A, active site volume of 440 Å3) or indazole (B, active site volume of 
190 Å3 and 77 Å3 for adjacent void) shown as orange and grey mesh respectively.  
Volumes calculated using the program VOIDOO (21). 
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Discussion 
Ligand Selection  
In order to successfully understand fatty acid binding, orientation, and 
positioning it was important to select ligands that would simultaneously satisfy 
several favorable properties.  These properties include: compounds with high affinity 
for CYP2E1, inducement of spectral shift so the complex is easily identified, and 
moderate water solubility for cocrystallization.  The ω-imidazolyl series of fatty acid 
analogs were closest to the fatty acid substrates metabolized by CYP2E1, satisfied the 
desired characteristics, and was easily generated through established synthetic 
protocols (5,8). 
Fatty Acid Analog Binding Site 
In previous work (Chapter 4) it was postulated that the residues of the 
conserved 216QxxNN220 may act as hydrogen bond donors to orient fatty acid 
substrates with the ω- or (ω-1)-carbon in the active site for metabolism.  The crystal 
structure described herein of CYP2E1 bound with the fatty acid analog ω-imidazolyl-
decanoic acid describes a different binding mode for fatty acid interaction with 
CYP2E1.  The CYP2E1 electron density map (omit σA-weighted 2FO−FC map 
contoured at 1.0 σ, Figure 5.1) shows continuous electron density from the imidazole 
ring of the decanoic acid analog to its carboxylate terminus.  The imidazole nitrogen 
coordinates directly to the heme iron while the carboxylate hydrogen bonds to N206 
in the F-helix.   
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The fatty acid analog cocrystallized with CYP2E1 is not the highest affinity 
compound examined in this series.  It did, however, possess the necessary balance 
between water solubility and affinity to facilitate cocrystallization with CYP2E1.  The 
binding data shows that the highest affinity ligand of the series is actually the ω-
imidazolyl-dodecanoic acid.  If ω-imidazolyl-dodecanoic acid binds in the same 
mode as ω-imidazolyl-decanoic acid, then the longer compound may have higher 
affinity because it may allow stronger interactions between that analog acid terminus 
and H109. H109 is opposite N206, the hydrogen bond donor in the CYP2E1/ω-
imidazolyl-decanoic acid complex and is a distance of 4.3 Å from the current ligand’s 
carboxylate.  It should also be noted that just beyond H109 is K243.  K243 has a 
distance of 10 Å from the current ligand’s carboxylate.  This series of three 
polar/positively charged amino acids (Figure 5.4 B) may allow for CYP2E1 to bind 
the broad range of fatty acid chain lengths that it is known to metabolize (24).   
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Figure 5.4:  The top two scoring access channels of CYP2E1 (A) as calculated by 
CAVER (22).  The yellow channel (path 1) was the highest scoring with magenta 
being second (path 2).  The polar residues lining the magenta channel are N206, 
H109, and K243 (B).  The polar residues lining the yellow channel are Q216, N219, 
and N220 (C). 
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Access Channel Calculations 
The same calculations that were utilized in the analysis of the most likely 
route for ligand entry and egress in the CYP2E1/indazole structure (described in 
Chapter 4) were also used to probe the CYP2E1/ω-imidazolyl-decanoic acid 
structure.  For the CYP2E1/indazole structure, CAVER (22) identified exit routes 
passing from the active site on either side of F478, through a large channel and 
ultimately exiting the protein between the B-B´ loop, the β1 sheet system, and beneath 
the F´ and G´ helices (Figure 5.4 A, path 1).  When the calculations were performed 
on the CYP2E1/ω-imidazolyl-decanoic acid structure the top result still exited the 
protein in the same position as previously described (Figure 5.4 A, path 1).  However, 
the second highest scoring result exited the protein between the B´ and G-helices 
above the I-helix (Figure 5.4 A, path 2).  This follows a similar tract to that of the 
VOIDOO calculated active site in the fatty acid analog structure (Figure 5.3 A).  The 
environment outside of these portals may suggest the different roles of the two paths.  
Path 1 exits the protein close to the putative membrane bound portion of the protein 
while path 2 exits on a face of the protein that is expected to be more exposed to the 
cytosol (Figure 5.5).  This may provide a path for hydrophobic substrates to enter the 
protein from the membrane via path 1, undergo metabolism in the active site, and exit 
through path 2 as the more hydrophilic metabolite.  
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Figure 5.5:  CAVER calculated cavities along with electrostatic surface.  The 
proposed membrane binding region of the N-terminus, and F′ and G′ helices are at the 
bottom of this protein structures in this orientation.  Two orientations are shown to 
illustrate the positively charged band of residues that would interact with polar head 
groups of the lipid bilayer.  The colors of the CAVER paths correspond with Figure 
5.4.  For orientation the heme is shown as green spheres.  
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Fatty acid binding residues and their conservation among species 
 As discussed in Chapter 1, CYP2E1 is so conserved among mammals that the 
name is retained between species.  Further, the CYP2E1 metabolism of fatty acids has 
been shown in several species using microsomal systems (9,25).  This suggests that 
the amino acid residues responsible for the orientation of fatty acids may be 
conserved.  The residue responsible for binding the carboxylate end of ω-imidazolyl-
decanoic acid in this structure is N206.  Further down exit path 2 (Figure 5.4 B) lie 
two additional positively charged amino acid side chains that may interact with the 
carboxylate of the longer fatty acids CYP2E1 is known to metabolize.   These other 
potential H-bond donors are H109 and K243.  Figure 5.6 shows sequence alignments 
of the regions of CYP2E1 containing N206, H109, and K243.  All three of these 
residues are primarily conserved across species with these exceptions: in rat and 
mouse H109 is another H-bond donator Tyr, and in rabbit it is Phe; in mouse K243 is 
Arg. 
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Figure 5.6: CYP2E1 species sequence alignment.  The primary sequence of human 
CYP2E1 from residues 61 to 300 were aligned with CYP2E1 from other mammalian 
species using CLUSTAL.  The conserved residues involved / proposed to be involved 
in fatty acid binding are highlighted:  H109 in blue with variations in gray; N206 in 
green; and K243 shown in yellow with variations in red.  Species abbreviations: 
human-Homo sapiens, pig-Sus scrofa, whale-Balaenoptera acutorostrata, bovine-Bos 
taurus, rhesus-Macaca mulatta, marmos-Callithrix jacchus, rat-Rattus norvegicus, 
mouse-Mus musculus, rabbit-Oryctolagus cuniculus, dog-Canis familiaris, and cat-
Felis silvestris catus. 
 
P05181       AQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGP 120 human 
Q8SQ64       AERYGPVFTVYLGSRRIVVLHGYKAVKEVLLHYKNEFSGRGEIPTFQVHKDKGVIFNNGP 120 pig 
A6BM02       AERFGPVFTLYLGSRRFVVLHGYKAVKEVLLDYRNEFSGRGETPAFQVHQDKGIIFNNGP 114 whale 
O18963       AERYGPVFTLYLGSQRAVVVHGYKPVKEVLLDYKNEFSGRGENPGFQMHKNNGIIFNNGS 120 bovine 
Q6GUQ4       AQRFGPVFTLYVGSRRVVVVHGYKAVREVLLDHKDEFSGRGDIPAFHAHRDRGIIFNNGP 120 rhesus 
Q6LEM3       AERFGPVFTLYLGARRVVVLYGYKAVREALLDYKSEFSGRGEIPAFREHKDRGIIFNNGP 120 marmos 
P05182       AKRFGPVFTLHLGSRRIVVLHGYKAVKEVLLNHKNEFSGRGDIPVFQEYKNKGIIFNNGP 120 rat 
Q05421       AKRFGPVFTLHLGQRRIVVLHGYKAVKEVLLNHKNEFSGRGDIPVFQEYKNKGIIFNNGP 120 mouse 
P08682       AERFGPVFTVYLGSRRVVVLHGYKAVREMLLNHKNEFSGRGEIPAFREFKDKGIIFNNGP 120 rabbit 
Q9MZY0       AEQYGPVFTLYLGSQRTVVLHGYKAVKEVLLDHKNDLSGRGEVFAFQSHKDRGITFNNGP 120 dog 
Q5KR53       AERYGPVFTLYLGSQRTVVLHGYKAVKEVLLDYKNEFSGRGEIYAFEAHKDKGITFNNGP 120 cat 
 
P05181       TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI 180 
Q8SQ64       TWRDTRRFSLTTLRDFGMGKQGNEQRIQREAHFLLEALRKTHGQPFDPTFLIGCAPCNVI 180 
A6BM02       TWQDTRRFSLTTLRDFGMGKQGNEQRIQSEAQLLLGALRKTHGQPFDPTFVIGFAPYNVI 174 
O18963       TWRDTRRFSLTTLRDLGMGKQGNEQRIQREAHFLLEVLRKTQGQPFDPTFVVGFAPYNVI 180 
Q6GUQ4       TWKDIRRFSLTTLRNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVI 180 
Q6LEM3       TWKDIRRFSLTALRNYGMGKQGNENRIQREAHFLVEALRKTQGQPFEPTFLIGCAPCNVI 180 
P05182       TWKDVRRFSLSILRDWGMGKQGNEARIQREAQFLVEELKKTKGQPFDPTFLIGCAPCNVI 180 
Q05421       TWKDVRRFSLSILRDWGMGKQGNEARIQREAHFLVEELKKTKGQPFDPTFLIGCAPCNVI 180 
P08682       TWKDTRRFSLTTLRDYGMGKQGNEDRIQKEAHFLLEELRKTQGQPFDPTFVIGCTPFNVI 180 
Q9MZY0       GWKDTRRLSLSTLRDYGMGKRGNEERIQREIPFLLEALRGTRGQPFDPTFLLGFAPFNVI 180 
Q5KR53       SWKDTRRLSLSILRDYGMGKRANEEQIQREVPFLLEAFRGTQGQPFDPTFVLGYAPCNVI 180 
 
P05181       ADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVA 240 
Q8SQ64       SDILFRQHFDYNDKTCLRLMSMFNENFYLLSTGWIQLYNNFSGYLRYLPGSHRKLMKNIS 240 
A6BM02       SDILFHKRADYNDKTALRMLSLFNENFYLLSSPWIQLYNNFPGYIRYLPGSHRKLIKNVS 234 
O18963       SDILFHKRFDYKDQTSLRLMSLFNENFYLLSSPWIQLYNNFPDYLQYLPGSHRKLLKNVS 240 
Q6GUQ4       ADILFRKHFDYNDEKFLRLMYLFNENFQLLSTPWLQLYNNFPSLLHYLPGSHRKVMKNVA 240 
Q6LEM3       ADILFRKRFDYDDEKFLRLMHLFNENFYLLSTPWLQLYNNFSTYLHYLPGSHRKVIRNVA 240 
P05182       ADILFNKRFDYNDKKCLRLMSLFNENFYLLSTPWIQLYNNFADYLRYLPGSHRKIMKNVS 240 
Q05421       ADILFNKRFDYDDKKCLELMSLFNENFYLLSTPWIQAYNYFSDYLQYLPGSHRKVMKNVS 240 
P08682       AKILFNDRFDYKDKQALRLMSLFNENFYLLSTPWLQVYNNFSNYLQYMPGSHRKVIKNVS 240 
Q9MZY0       ADILFHKHFDYSDQTGLRIQKLFNENFHLLSTGWLQLYNIFPSYLHYLPGSHRKVLRNVA 240 
Q5KR53       SDILFRKRFDYRDQTGLRIQKLFNENFHLLSTNWLQLYNIFPSYMRYLPGNHRKVIKNVY 240 
 
P05181       EVKEYVSERVKEHHQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG 300 
Q8SQ64       EIKDYALERVKDHRDSLEPSCPRDFTDTLLMEMEKEKYSAEPIYTLDNIAVTVADMFFAG 300 
A6BM02       EIKEYALEGVKDHQKSLEPSCPRDFTDTMLMEMEKEKHSTDPVYTLDNIAVTVADLLFAG 294 
O18963       EVKSYALERVKDHQKSLEPSCPRGFLDTMLIEMAKERHSVDPMYTLENIAVTVADLLFAG 300 
Q6GUQ4       EIKEYVSERVKEHLQSLDPNCPRDLTDCLLVEMEKEKHSAERLYTMDGITVTVADLFFAG 300 
Q6LEM3       EIKEYVSERVKEHYQSLDPNCPRDLTDCLLVEMEKEKPSAEPLYTMDGITVTVADLFFAG 300 
P05182       EIKQYTLEKAKEHLQSLDINCARDVTDCLLIEMEKEKHSQEPMYTMENVSVTLADLFFAG 300 
Q05421       EIRQYTLGKAKEHLKSLDINCPRDVTDCLLIEMEKEKHSQEPMYTMENISVTLADLFFAG 300 
P08682       EIKEYTLARVKEHHKSLDPSCPRDFIDSLLIEMEKDKHSTEPLYTLENIAVTVADMFFAG 300 
Q9MZY0       ELKDYSLERVKEHQESLDPTCSRDFTDCLLQELQKERYGTEPWYTLDNIAVTVADLFFAG 300 
Q5KR53       EIKSYTAARVKEHEESLDPNCPRDFTDSLLLEMRKERYTKEPWFTFDNIAATIADLFFAG 300 
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As previously mentioned, in addition to the metabolism of medium length 
fatty acids, CYP2E1 is known for the oxidation of eicosanoids (26,27).  Two 
important arachidonic acid metabolites generated by CYP2E1 (along with other 
CYPs) are the 20-hydroxyeicosatraenoic acid (20-HETE) and 19-
hydroxyeicosatraenoic acid (19-HETE).  These metabolites are potent signaling 
molecules in that 20-HETE has been shown to be a vasoconstrictor (28) where 19-
HETE has been shown to be a vasodilator (29).  In previous work (Chapter 4), a 
binding mode for arachidonic acid was proposed along the large channel (Caver path 
1).  If arachidonic acid binds along path 2 like the fatty acid analog shown in this new 
complex, interactions of the arachidonic acid carboxylate with K243, could also 
position this substrate for ω- or (ω-1)-hydroxylation (Figure 5.7). 
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Figure 5.7:  Arachidonic acid manually docked into the CYP2E1 structure, shown in 
wall-eyed stereo view.  Arachidonic acid (shown in light blue) was manually docked 
into the substrate access channel path 2 positioning the arachidonic acid carboxylate 
for hydrogen bonding to K243 and opposing terminus for ω- or (ω-1)-hydroxylation. 
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 Comparison of CYP2E1 and P450BM3 bound with fatty acid analogs 
As previously discussed, an ω-imidazolyl fatty acid analog has been 
cocrystallized with P450BM3.  To understand the similarities and differences 
between the CYP2E1 and P450BM3 complexes with fatty acid analogs the structures 
were superimposed using secondary structure matching (30).  The alignment showed 
significant differences in the overall structure with a R.M.S.D. of the Cα atoms of 
3.14 Å (Figure 5.8A).  This is not surprising due to the low sequence identity (~20%) 
between the two proteins.  Upon more detailed inspection the two proteins bind fatty 
acid analogs in very different orientations (Figure 5.8B). The carboxylates of these 
ligands oriented in opposite directions with respect to each other in the enzyme active 
sites.  Both enzymes catalyze the sub-terminal hydroxylation of fatty acids (CYP2E1 
mainly ω-1 and P450BM3 mainly ω-2 but also ω-1 and ω-3 (31)) at similar positions 
along with the formation of epoxides on unsaturated fatty acids (32,33).  While the 
relationship of these proteins is an example of convergent functions, the structures are 
divergent. 
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Figure 5.8:  Structural overlay of CYP2E1 and P450BM3 bound with fatty acid 
analogs.  The structures of CYP2E1 (red, heme in black) bound with ω-imidazolyl-
decanoic acid (magenta) and P450BM3 (blue, heme in black) bound with N-(10-
imidazolyldodecanoyl)-L-leucine (teal) were superimposed using secondary-structure 
matching (30) in COOT (17) with a Cα root mean square deviation of 3.14 Å.  There 
are considerable differences in the overall structure (A) contributing the different 
ligand binding modes shown in the active site cross section (B). 
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Conclusions 
 In summary, the structure of CYP2E1 bound to the fatty acid analog, ω-
imidazolyl-decanoic acid, has shown that subtle active site changes can allow the 
active site volume to more than double to accommodate fatty acids.  This active site 
flexibility opens a different portion of the protein for fatty acid binding than 
previously proposed.  In addition, it opens another location for potential access/egress 
to/from the active site.   Future work is needed to fully understand how CYP2E1 
acclimates to even larger fatty acids such as arachidonic acid, whose metabolism has 
a significant physiological impact. 
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Chapter 6. 
Conclusions 
 The work described in this thesis focused on the two CYP isoforms: 
CYP2A13 and CYP2E1.  These enzymes are important because of their involvement 
in xenobiotic metabolism and the associated subsequent toxicity.  Understanding the 
individual active site topology of these xenobiotic-metabolizing enzymes is important 
to understand both their pharmacological and toxicological roles.  
In the first crystal structure of CYP2A13, density of unknown origin was 
found in the enzyme active site.  Several factors suggested that the ligand might be 
indole or an indole metabolite so an existing method for detecting indole in bacterial 
culture was modified to a more sensitive HPLC-UV/Vis-MS/MS method that could 
differentiate between indole and several oxidized forms of indole.  The method was 
used to analyze protein used for crystallization and definitively identified 
unsubstituted indole in the solution, leading to its subsequent modeling into the 
CYP2A13 active site electron density.  
The first crystal structure of CYP2E1 was solved with two different ligands 
bound.  Initially the structure of CYP2E1 was solved with the small molecular weight 
inhibitor indazole.  This structure showed a protein with the typical P450 fold.  The 
active site was compact (190 Å3), hydrophobic, and smaller than any other CYP 
structurally characterized.  This active site morphology was consistent with the 
CYP2E1 role in metabolism of small molecular weight substrates.  Directly adjacent 
to the active site lies a channel that extends to the enzyme surface that has been 
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proposed to allow access of substrates to the CYP catalytic core.  An additional void 
with a volume of 77 Å3 is distal to the active site cavity with the residues of F106, 
F116, and F298 separating the two voids. 
CYP2E1 is also known to metabolize fatty acids and it was still unclear what 
active site conformational changes were necessary to bind the larger substrates.  It 
was postulated from the indazole-bound CYP2E1 structure that fatty acids could 
extend from a group of polar amino acid in the substrate access channel into the 
active site to position the ω-teminus of the fatty acid for ω-1 metabolism.  To 
investigate the validity of this proposal, CYP2E1 was cocrystallized and the structure 
solved with a fatty acid analog, ω-imidazolyl-decanoic acid.  The movement of F298 
allowed merging of the active site and the small adjacent empty cavity increasing the 
active site volume to 440 Å3. The carboxylate of this analog hydrogen bonds directly 
to N209 of the F-helix, which is far from the previously proposed polar amino acids 
of the substrate access channel.  This active site flexibility may also allow for the 
binding of the larger fatty acids (like arachidonic acid) that CYP2E1 is also known to 
metabolize. 
 This research provides important new information about ligand binding in two 
human CYP enzymes that will be useful in predicting CYP metabolism, designing 
drugs that are resistant to CYP metabolism, and designing pro-drugs that will be 
metabolized by these enzymes.  In the case of CYP2E1, the structure can be used as a 
basis for the design of selective inhibitors to prevent the toxicity of acetaminophen 
overdose.  Future work should focus on confirming the binding modes of larger fatty 
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acid molecules, like arachidonic acid, whose metabolites play important physiological 
roles.  
